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Introduction: Airway mucus hyper-secretion is the main cause of mortality and morbidity in respiratory 
diseases such as asthma and chronic obstructive pulmonary disease (COPD) and is the leading cause 
of death in South Africa. Mucus is a viscid, slimy visco-elastic gel-like material, which coats the 
epithelial tissue of gastrointestinal, reproductive and respiratory tracts. Mucus has defined rheological 
properties that enable it to be transported out of the lungs by mucociliary clearance. Mucins are high-
molecular weight, heavily O-glycosylated glycoproteins that comprise approximately 2% of mucus 
and cause the mucus to be thick and tenacious. Mucins are divided into three broad categories namely, 
secreted gel-forming, secreted non-gel forming and membrane bound. 
Methods: Sputum samples were collected in 6M GuHCl containing protease inhibitors from patients 
with asthma and COPD from hospitals around Cape Town and from a group of non-symptomatic 
volunteers who comprised a control group. Mucins were purified using caesium chloride density 
gradient ultracentrifugation and identified by western blot analysis using MUC antibodies to specific 
mucins in the respiratory tract. Ion-exchange chromatography was used to separate the mucins based 
on their charge and used to detect whether there are different glycoforms present between mucins. 
Results: Mucins eluted at a density of 1.39 – 1.40g/ml in a CsCl density gradient ultracentrifugation. 
Mucins eluted as a broad peak from the Mono Q 5/50GL column. The PAS positive fractions were 
further examined for the presence of MUC5AC, MUC5B and MUC2. The results showed an inter-
individual variation in all three groups. MUC5AC and MUC5B were found in both asthma and COPD. 
However, MUC2, a mucin that only presents in the disease state was found in asthma and in COPD and 
in three normal volunteers. The presence of MUC2 in asthma over and above MUC5AC and MUC5B 
(all three are secreted gel-forming mucins) could change the rheological properties of the mucus gel 
in the airways resulting in an even more tenacious secretion that aggravates the disease. The fact that 
MUC2 was found in asthma and COPD and in some normal volunteers shows that these diseases have 











Conclusion: The presence of MUC2, a gel-forming mucin, in airway disease could be an indicator 
for disease severity for those already suffering from respiratory diseases and an indicator of disease 
for healthy volunteers that present with MUC2. The presence of MUC2 in only 3/10 normal healthy 
volunteers, 8/15 asthma and 7/15 COPD samples tested shows there is some inter-individual variation 
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This study was concerned with the isolation, purification and biochemical characterisation of mucus 
and mucins found in the respiratory tracts of patients suffering from chronic airway diseases namely, 
asthma and COPD and of normal healthy volunteers.
The aim was to analyse these respiratory mucins by biochemical methods and to make a comparison 
between asthma and COPD and then to compare these respiratory mucins with those found in healthy 
individuals. This is the first study of its kind in South Africa focusing on patients currently attending 
respiratory clinics around Cape Town, and the first to compare asthma and COPD in a single study. No 
other respiratory complications were present in our sample group.
The First Chapter gives a brief overview of mucus and mucins found in the respiratory tract and 
elsewhere in the body. It explains where specific mucins are expressed and the condition in which this 
occurs. 
Chapter 2 explains the materials and methodology used in this study. The methods used were caesium 
chloride density gradient ultracentrifugation to purify mucins, ion-exchange chromatography to 
separate mucins based on charge, agarose gel electrophoresis and western blot analysis to identify the 
mucins. 
Chapter 3 to Chapter 7 show the results found in each group, from the isolation and purification steps 
to the identification of the mucins present in these groups. 
Chapter 8 shows the amino acids found in the mucins from the 3 groups under investigation.












There is an up-regulation of respiratory mucins MUC5AC and MUC5B in diseased states. More 
interestingly MUC2, present in small amounts in chronic airways has been found in asthma, COPD 
and also in normal groups. 
1.1 Literature review
Airway mucus hypersecretion is the main feature in respiratory disease that leads to morbidity and 
mortality (Kim 2003; Rogers 2004; Rose and Voynow 2006). The lung uses specialised secretions 
produced by the airways to provide a renewable and transportable protective layer to interact with, 
neutralise and remove inhaled toxic materials trapped in mucus (Samet and Cheng 1994). 
1.2 The general role of mucus
Mucus is a viscid (viscous), lubricious viscoelastic gel-like material which coats the epithelial surface 
of the gastrointestinal, reproductive and respiratory tracts of the body and plays a significant role in 
the vertebrate (as a protective function) and invertebrate (as a lubricant) kingdoms (Reid and Clamp 
1978; Sharma et al, 1998). Airway mucus is a tenacious solution with defined rheological and chemical 
properties that enable it to be transported out of the lungs by muco-ciliary clearance (Samet and Cheng 
1994; Lamblin et al, 2001). 
Muco-ciliary clearance is a natural defence mechanism which the immune system uses against inhaled 
pathogens to keep the lower airways sterile (Lamblin et al, 2001). It involves the removal of excess 
mucus produced by the goblet cells that line both the upper and lower surface epithelial layer which is 
covered with cilia that beat rapidly in a co-ordinated fashion, propelling particles trapped in the mucus 
layer up to the pharynx and out by either swallowing or coughing, see Figure 1-1 (Rubin 2002). Figure 
1-1 also shows the removal of mucus from the lungs by coughing, another natural defence mechanism 
the body uses.
Mucus is an essential component of the protective biofilm covering the mucosal surfaces of the body 
and has specialized functions depending on the organ (Rose et al, 2001; Rogers 2007). The major types 
of mucus producing organs are the airway/respiratory, digestive and reproductive systems (Gevers 
1987). Mucus protects the airway epithelium from dehydration and inhaled infectious and toxic agents 











protein (1%), lipids (1%) and inorganic salts (1%) (Allen 1984; Rogers 2007; Ke et al, 2008).
Figure 1-1: Shows the natural removal of mucus by ciliary clearance (top)
 and cough clearance (bottom) (Rubin 2002).
1.2.1 Mucus of the respiratory system
Airway mucus consists of large oligomeric gel forming glycoproteins (mucins) with varying molecular 
masses that range between 10 and 40 million Daltons. The polymer matrix of mucus is provided 
by large mucins, which in the airways, are produced by two different secretory cell populations: the 
surface epithelial goblet cells and the mucous cells in the submucosal glands (Hovenberg et al, 1996; 
Groneberg et al, 2002). Secretory cells include serous, mucosal and seromucosal cells of the submucosal 
glands and goblet cells in the airway surface epithelia (Rose 1992). 
In normal airways, the removal of the excess mucus, the presence of which is caused by the invasion 
of pathogens to the respiratory tract, is done by either coughing, ciliary motion or lymphatic drainage 
(Widdicombe 1978). As explained above, ciliary clearance is the removal of mucus by the action of 
cilia, which is aided by the secretory and membrane-tethered mucins as part of the innate immune 
defence system. Coughing depends on the viscosity, elasticity and thickness of the mucus. When 
the cilia are overloaded, the mucus will stimulate the cough receptors to induce coughing (Rose and 
Voynow 2006). The primary role of mucins in the respiratory tract is that of muco-ciliary clearance 











In healthy airways there is a low production of mucus that protects the airways efficiently,  whereas 
in the diseased airways there is a high production of mucus (Thornton and Sheehan 2004; Thornton et 
al, 2007). Mucus protects the respiratory epithelium from dehydration in the normal airways (Kim S 
2005). The major respiratory mucins are MUC5AC and MUC5B (Rose et al, 2001).
Mucus increases in viscosity in the diseased airways compared to normal and also differs in the cross 
linking, size, acidity and appearance (Rogers 2004). These differences lead to the formation of a mucus 
plug that is present only in the diseased airways. The increased mucus in diseased states leads to 
mucociliary clearance impairment and inflammation caused by inhaled insults (Kim 1997). Airway 
mucus hypersecretion is a key pathophysiological feature in many patients with asthma and chronic 
obstructive pulmonary disease (COPD) (Rogers 2000). Mucus and mucins are overproduced in airways 
of patients with chronic airway disease. Figure 1-2 shows the production of mucus and the excess 
mucus produced by goblet cells in the diseased conditions (Rose and Voynow 2006).
Reduction in muco-ciliary clearance due to over-production of mucus leads to increased susceptibility 
to lung infections. These two chronic lower airway respiratory diseases, asthma and COPD, lead to 
lung function failure and ultimately death. In diseased states the glands are enlarged due to mucous cell 
hyperplasia which can be seen in mucus hypersecretory diseases such as asthma and COPD (Rogers 
2004). Airway inflammation is considered to be the primary cause of airway disease such as asthma 
and COPD (Hargreave 1999). The inflammatory mediators produced by these respiratory diseases 
differ from each other. In asthma patients, there are more eosinophils produced than in COPD patients, 
where there are more neutrophils produced.
The common features of airway hypersecretion in these respiratory diseases are sputum production and 











Figure 1-2: A schematic diagram of the airway secretory cells response to acute and chronic
challenges (Rose and Voynow 2006).
In healthy airways the mucus layer is thin and coats the cells to keep them hydrated and in an ideal 
environment, but this mucus is over-produced in chronic airways as a form of protection. This becomes 
harmful to the airways because of the excess mucus blocking the free flow of air in and out of the lungs.
1.2.2 Mucus of the gastrointestinal tract
Mucus forms a gel that provides a protective barrier and a stable unstirred layer at the enteric interface 
between the stomach and the duodenum. It shields the mucosa from strong acids, proteases and injurious 
action of food or foreign material (Gevers 1987; Taylor et al, 2005). Mucus in the gastrointestinal 
(GI) tract lubricates the passage of solids, undigested foods and faeces through the gut lumen and 
protects the tract from mechanical damage resulting from the removal of waste after digestion (Allen 
1984). The mucus bicarbonate barrier in the stomach is responsible for the neutralisation of the lumen, 
allowing protection against acids and also acting as a barrier to pepsin digestion of the underlying 
gastric epithelia (Bhaskar et al, 1992; Allen and Flemstrom 2005). Mucins found in the GI tract are 











1.2.3 Mucus of the reproductive system
Mucus produced from the cervix forms a protective barrier against infection, with a mucus plug at the 
mouth of the cervix during pregnancy for added protection (Sheehan and Carlstedt 1984; Lagow et 
al, 1999).  The viscosity of this mucus depends on the timing of the menstrual cycle (Van Kooij et al, 
1980). During mid-cycle, the mucus is more watery, thin and in strands, to facilitate the movement of 
sperm to the cervical tract (Argueso et al, 2002). During the rest of the cycle, it is viscous and tends 
to form a plug at the cervix. The primary functions of these mucins are to (i) aid in fertilization, (ii) 
prevent infection and (iii) act as a lubricant during sexual intercourse (Elstein 1978; Gevers 1987). 
There are eight types of mucin found in cervical mucus namely, MUC1, MUC2, MUC4, MUC5AC, 
MUC5B, MUC6, MUC8 and MUC9 (Gipson et al, 1997; Lagow et al, 1999). 
1.2.4 Mucus of the nasal cavity
Nasal mucus produced from the mucosa serves to protect the respiratory tract from environmental 
irritants. Together with foreign particles trapped by the mucus, it turns hard and is easily removed. 
Watery mucus leads to a runny nose and could be the first signs of a cold or infection. The major 
mucins found in the normal human nasal tissue are MUC5AC produced in the goblet cells in the 
epithelial surface and MUC5B from the submucosal glandular cells (Groneberg et al, 2003). 
1.3 Mucins (Mucous glycoproteins)
The isolation and characterisation of individual components of mucus are required to understand 
the relationship between mucin structure and physical properties of mucus (Chace et al, 1985). The 
substance that gives the mucus its viscous and gel-forming properties, mucins (mucous glycoproteins) 
are responsible for the rheological properties of mucus. Mucins are the major macromolecular 
glycoconjugates of mucus, the mucosal layer that protects and lubricates the epithelial lining of the 
body (Rose 1992; Thornton et al, 2007). 
Mucins are comprised of approximately 80% carbohydrate and 20% protein. The carbohydrate 
is composed of five different monosaccharides namely; N‑acetylgalactosamine (GalNac), 
N-acetylglucosamine (GluNac), galactose, fucose and sialic acid (Allen 1984; Van Klinken et al, 1998). 
The carbohydrates are important for mucin structure and contribute to the rheological and viscoelastic 











Mucins are high molecular weight glycoproteins, polydisperse in mass (2-4 x 106) and size (0.5-
10µm). These linear molecules contain sites of extensive O-glycan attachments (mucin-like domains) 
(Rose et al, 1984; Thornton et al, 1997; Thornton and Sheehan 2004; Thornton et al, 2007), that are 
secreted by epithelial cells lining mammalian respiratory, gastrointestinal and reproductive tracts and 
provide the viscoelasticity required for efficient mucous‑cilia interactions (Rogers 2004). Mucins have 
a protein backbone that contain numerous tandem repeats that are rich in serine and threonine residues 
which are sites for O-glycosidic linkage of N-acetylgalactosamine to the hydroxyl moieties of serine 
and threonine (Kim S 2005; Rose and Voynow 2006).
A generic diagram (Figure 1-3) depicts a mucin structure showing the interactions between the 
carbohydrates and the protein, with the O-glycosylation interaction between the hydroxyl amino acids 
and GalNac at the gene level. The carbohydrates are attached to the polypeptides by O-linkage and 
results in a stiffened large molecule that leads to mucins being space filling which aids in their gel 
making properties (Thornton and Sheehan 2004). 
Figure 1-3: Shows a schematic representation of a mucin structure (Lamblin et al, 2001). 











Mucin apoprotein (apomucin) is the primary gene product which is encoded by MUC genes which fall 
into three broad categories namely: gel-forming secreted mucins such as MUC2, MUC5AC, MUC5B, 
MUC6 and MUC19; non-gel forming and secreted MUC7, MUC8 and MUC9 and the rest that are 
membrane bound (Rose 1989; Audie et al, 1993; Thornton et al, 1996). Trans-membrane mucins give 
cells their polarity. Eight of the 21 mucin genes to date are well characterised. These mucins are organ-
specific, for example, the stomach has MUC5AC, MUC6 and the colon has MUC2. Figure 1‑4 shows 
examples of the different types of mucin found in the body. 
Figure 1-4: Shows secreted gel and membrane bound mucins
(www.medkem.gu.se/mucinbiology/mucin.gif- June 2008).
Lung mucus containing mucins in healthy airways contributes to the mucociliary defence system that 
protects the lungs against environmental influence (Rose and Voynow 2006). An airway mucin, such 
as MUC5AC as shown (Figure 1.5), is one of the major core proteins of secreted polymeric mucins 
found in the goblet cells of the airway surface epithelium (Kaneko et al, 2003; Cohn 2006; Thornton 
et al, 2007). MUC5B is the other major core protein which is a secreted polymeric mucin, found in 
the submucosal (tracheobronchial) glands specifically in the mucous glandular cells (Hovenberg et al, 
1996; Sharma et al, 1998; Wickstrom et al, 1998; Thornton et al, 2007). A small amount of MUC2, 
a secreted mucin like MUC5AC but smaller in size, if present, will be detected in very low levels in 











The airways consist of two types of cells namely, goblet cells and the submucosal glands that synthesize 
mucins (Rose et al, 1984; Kim et al, 1997). Goblet cells found in the surface epithelium, upon interaction 
with environmental irritants, shows a marked increase of mucus produced for protection. The secreted 
mucins are a fundamental component of the mucosal barrier (Thornton et al, 2007). The second cell 
type is the submucosal glands, which consist of mucous and serous cells. Both these cell types produce 
secreted polymeric mucins.
1.4 Respiratory airway mucins
In the respiratory tract there are a number of cells that produce mucus which are situated in the surface 
epithelium namely, serous cells found in foetal and not adult airways, mucous cells which are present 
throughout the airways and Clara cells which are found on the periphery and only in the intrapulmonary 
regions (Reid and Clamp 1978). 
There are six mucins found in airway secretions namely: (i) MUC1, a transmembrane mucin that is 
localised and tethered to the apical membrane of the surface epithelial cells and to serous glands by 
its C-terminal subunit. (ii) MUC2, a secreted intestinal mucin expressed in the surface epithelial cells. 
(iii) MUC4, a cell-associated mucin expressed in both the surface and glandular cells. (iv) MUC7, 
a secreted salivary mucin expressed solely in the glands. (v) MUC5AC, a large cysteine-rich, gel-
forming, secreted mucin found in the surface epithelium layer and (vi) MUC5B, another gel-forming 
secreted mucin found in the submucosal glands of the respiratory tract (Groneberg et al, 2003). These 
major respiratory mucins were present in bronchial washes from normal patients and those that have 
chronic airway disease. 
The oligomeric secreted mucin genes found in the respiratory tract of humans (MUC5AC, MUC5B, 











Figure 1-5: Mucus in chronic airway diseases (Cohn 2006).
1.5 Mucus and mucins in asthma
Asthma is a pulmonary disease in which there is an obstruction to the flow of air out of the lungs but 
unlike other respiratory diseases, this obstruction is reversible. Asthma is a chronic inflammatory airway 
disease that is characterized by inflammatory cells such as mast cells, eosinophils and T‑lymphocytes, 
bronchial hyper-responsiveness and mucus hypersecretion (Groneberg et al, 2002). 
Figure 1-6 represents the stages the lung undergoes when an asthma attack occurs. The airways become 
narrower during inflammation and there is an over‑production of mucus. During a bronchospasm, air 
is prevented from passing through the trachea into the alveoli, thus blocking the passage of the oxygen 











Figure 1-6: A representation of an asthma attack. The normal airway, airway with inflammation, 
bronchospasm and mucus production.  (http://www.network-health.org/tpl/health_464.
asp?contid=health_asthma_lungs – February 2009).
Mucus hypersecretion is a main feature of asthma as seen by the increase in sputum production during 
an acute exacerbation which is associated with a decrease in FEV1 (Kim S 2005). The mucus in sputum 
of an asthma patient is very viscous and contains DNA, lactoferrin, eosinophils, cationic protein and 
plasma protein (Rogers 2004). Other pathological features of asthma are mucous plugging, goblet-cell 
hyperplasia, smooth muscle hypertrophy, submucosal gland hyperplasia, thick basement membrane 












These pathological characteristics lead to mucus obstruction with increased luminal mucus which in 
turn leads to airway remodelling (Rose et al, 2001; Morcillo and Cortijo 2006). There is severe scarring 
of the epithelial lining that occurs during these attacks by the inhaled agents or inflammatory cells 
that are recruited to aid the airways in response to injury. The repair process involves epithelial cell 
migration, proliferation and integrity of the airway epithelium restoration. This damage control that the 
airways undergo is called airway remodelling. 
Airway remodelling is the structural changes of the airways, which are characterised by the thickening 
of the airway wall, associated with loss of epithelial organisation, goblet-cell hyperplasia, sub-
epithelial fibrosis, increased vascularisation, fibroblast and myofibroblast proliferation, and smooth‑
muscle hyperplasia and/or hypertrophy (Elias et al, 1999; Inman 2004; Bai and Knight 2005). 
Goblet-cell hyperplasia in the airways leads to different levels of severity of asthma which leads 
to specific inflammatory and immune response mediators that activate mucin gene regulation and 
airway remodelling (Rose and Voynow 2006). This abnormality in goblet cells contributes to the 
pathophysiological changes that occur in the normal function of the mucin stores and production (Rose 
et al, 2001). 
Figure 1-7: Airway remodelling (Kim S 2005).
The main cells that are associated with the changes in the epithelium and submucosa in the respiratory 
airways of people suffering from asthma are the eosinophils and the Th2-lymphocytes. Neutrophils 
have been found to be present in sputum of asthma sufferers. Airway remodelling is depicted in Figure 











Figure 1-8: Mechanisms of acute and chronic inflammation in asthma
and remodelling processes (Bousquet et al, 2000).
1.7 Mucus and mucins in COPD
Chronic obstructive pulmonary disease (COPD) is one of the most common respiratory diseases in 
the world (Barnes 2003). COPD is a disorder that persistently obstructs bronchial airflow and consists 
of chronic bronchitis (hypersecretion of mucus, chronic cough and sputum production), chronic 
bronchiolitis (small airway disease/chronic inflammation of the peripheral airways) and emphysema 
(airspace enlargement due to alveolar destruction) (Rogers 2000; Barnes 2003; Kim S 2005; Minai et 
al, 2008).
It is a heterogeneous syndrome characterised by the relentlessly progressive limitation of airflow, 
associated with abnormal lung inflammation in response to noxious gases or particles and is poorly 
reversible (Barnes 2004; Hogg et al, 2004; Minai et al, 2008). The term “Obstructive” means that the 
person finds it difficult to exhale which leaves stale (deoxygenated) air in the lungs and reduces the 
amount of new (oxygenated) air the person can inhale with the next breath (Standifer et al, 2006). 











Figure 1-9: The effect of COPD on the airways. The picture depicts the effects of two of the diseases 
that comprise COPD, on the bronchus and alveoli of the lung. 
(http://healthguide.howstuffworks.com/COPD - June 2008).
1.7.1 Pathogenesis of COPD
One of the main causes of COPD is smoke, especially cigarette smoke. The long-term exposure to 
cigarette smoke leads to an inflammatory response in the lower respiratory tract that is a progressively 
and poorly reversible airway obstruction and causes small airway remodelling (Hogg et al, 2004; 
Minai et al, 2008). COPD will reduce life expectancy and cause disabilities much faster if the patient 
continues to smoke, because the airflow limitation that results from this disease causes fixed narrowing 
of the small airways, emphysema and luminal obstruction with mucus production (Barnes et al, 2003; 
Barnes 2004). 
There are inflammatory cells and inflammatory mediators that induce the expression and production 
of respiratory mucins, especially the production of MUC5AC and a small amount of MUC5B (Fabbri 
et al, 1998; Kim S 2005; Hogg et al, 2007). Other stimuli such as oxidative stress, bacterial exo-
products due to infection and pro‑inflammatory cytokines namely, TNF‑α and IL‑1β  and the presence 
of cigarette smoke, all induce an inflammatory response in COPD, mucin hyper‑production and mucus 
hypersecretion in the respiratory tract (Maestrelli et al, 2001; Takeyama et al, 2001; Perrais et al, 2002; 
Barnes et al, 2003; Dicpinigaitis 2003; Shao et al, 2004). 
The symptoms of COPD are the presence of persistently abnormal lung function, cough, sputum 











accumulation of inflammatory exudates in the lumen, which infiltrates the wall of the trachea by airway 
remodelling.  The obstruction of small airways in COPD is associated with airway wall thickening by 
means of the remodelling process that aids in the repair of the lung tissue, damaged by the malfunction 
of mucociliary clearance, the natural and first line of defence (Hogg et al, 2004).
Chronic bronchitis is an inflammatory disease characterised by the presence of a persistent cough 
with sputum production on most days for at least three months in two consecutive years without any 
explanation (Samet and Cheng 1994; Jeffery 2000; Turato et al, 2001; Hogg 2008). The key features 
of chronic bronchitis are the mucus production and inflammation of the bronchial wall (Yoshida and 
Tuder 2007). 
Chronic obstructive bronchiolitis (fibrosis) or small airway obstruction is another pathological hallmark 
of COPD, and is characterised by inflammation of the peripheral airways and airflow limitations, due 
to narrowing of and obliterating the lumen that leads to the deterioration and constriction of the tiny 
airways that provides oxygen to the body (Jeffery 2000; Turato et al, 2001). 
Emphysema is a progressive disease which causes permanent lung destruction and airflow obstruction 
and reduces gaseous exchange with symptoms of dyspnoea (Turato et al, 2001; Barnes 2006; Minai 
et al, 2008). This disease reduces the quality of life attested by the worsening of pulmonary function, 
exercise capacity and continuous deterioration of functional status (Minai et al, 2008).
1.7.2 Mucolytics
The mucolytics serve two functions, namely, (i) to increase the ability to expectorate sputum or (ii) 
to decrease mucus hypersecretion. They dissolve the mucus by hydrolysing glycosaminoglycans and 
reducing the viscosity of the mucus, making it thin and easier to cough out (en.wikipedia.org/wiki/
Expectorant-July 2008). An example of a mucolytic drug, N-acetylcysteine, is one that is commonly 
used today. Other drugs that are used are carbocysteine and mecysteine hydrochloride which reduce 
the viscosity of bronchial secretions by cleaving disulphide bonds cross-linking mucus glycoprotein 
molecules (Dawson et al, 2002). Corticosteroids, which are commonly used to treat inflammatory 











1.8 Asthma and COPD
Asthma and COPD are two diseases that cause narrowing of the airways due to inflammation. The 
plugging of the airways is caused by the over‑production of mucus in response to inflammation. 
There are currently two hypotheses about the definition of asthma and COPD namely, the British and 
the Dutch Hypotheses. The British hypothesis claims that asthma and COPD are two different entities 
whereas the Dutch hypothesis claims they are different expressions of one disease. 
According to the Dutch hypothesis, asthma and COPD are not completely distinct diseases and have 
common underlying mechanisms leading to the pathology of both these disorders (Van der Pouw Kraan 
et al, 2002; Bleecker 2004). Some similarities would be expected between these diseases as the lung 
responds in a limited manner to airway obstruction (Chhabra 2006). The similarities between these two 
chronic respiratory diseases are that they both cause airflow obstruction, chronic inflammation, mucus 
production, bronchoconstriction, are involved with the small airways and are consequences of gene‑
environmental interactions (Dodge et al, 1986; Barnes 2004; Bleecker 2004). 
The differences between asthma and COPD for this study depended on the amount and type of mucus 
produced in response to these diseases. In COPD the mucus (Figure 1-10) is (i) less viscous and without 
marked plasma exudation, (ii) the ratio of mucin MUC5AC: MUC5B may be reduced, (iii) there is full 
release of mucin into the airway lumen, rather than tethering of mucus to epithelial cells as in asthma 
(Rogers 2000) and (iv) the mucus in COPD is more fluid because of the presence of neutrophils which 
cleave the mucus from the lumen, in contrast to asthma which produces eosinophils which cannot 
cleave it from the lumen (Rogers 2004). The neutrophils contain proteases that cleave the mucus thus 
allowing it to flow more easily. MUC5AC is more susceptible to proteolytic degradation than MUC5B 
as seen, for example, in patients that suffer with cystic fibrosis (Davies et al, 1999). 
Another way to determine the differences between asthma and COPD is by looking at the systemic 
inflammatory markers present in the blood of patients suffering from these diseases. Higashimoto et al, 
2008, 2008 showed that these diseases share common markers but certain systemic inflammatory markers 
may reflect differences in the serum especially when looking at TGF‑β1 and α1‑AT (Higashimoto et al, 











Figure 1-10: A schematic showing the differences between asthma and COPD response
to inflammation compared to normal healthy subjects (Rogers 2004).
The aim of this study was to analyse by biochemical methods mucins found in the respiratory tract 
of patients suffering from respiratory diseases such as asthma and COPD and to make a comparison, 
firstly between these diseases and then with mucins found in normal healthy individuals. Attention was 
focused on the different charge forms of mucins and their association with normal healthy individuals 
and asthma and COPD patients. 
In the case of asthma, patients who die of status asthmaticus have a condition where the mucus plugs 
the airways causing the patients to have difficulty in exhaling, resulting in asphyxiation. It is believed 
that MUC5B, a secreted gel-forming airway mucin, has two glycoforms of different charges. These 
different charge forms (glycoforms) are released from the airways at different times. It is hypothesised 
that the second glycoform causes the mucus to be so thick that it forms a plug occlusion resulting in 
death. This is not the case in COPD, where the mucus is very fluid and no mucus plug forms. 
A further aim of this study was to look at these diseases simultaneously in a controlled setting, which 











sputum samples collected from patients who attend the clinics around Cape Town, South Africa, for 
treatment of the above-mentioned respiratory diseases and not from post mortem samples as previously 
reported (Sheehan et al, 1995). Evidence from HPLC analysis, agarose gel electrophoresis and Western 
blot analysis showed that the major respiratory mucins found in people that suffer from asthma and 
COPD are MUC5AC and MUC5B. The presence of MUC2 found in a few of the diseased samples 
could be an indicator for disease progression. The up-regulation of MUC5AC was prominent in normal, 
asthma and COPD as it was seen in greater quantities than the other respiratory mucins. The fact that 
MUC5B was present in all 3 groups could be an indicator of disease and interestingly, the presence of 
MUC2 in these groups could be an indicator of disease severity.
Patients with asthma and COPD exhibit characteristics of airway hypersecretion namely, sputum 
production, luminal mucus, submucosal gland hypertrophy and goblet-cell hyperplasia (Rogers 2001). 
Our aim was to establish the differences between asthma and COPD by looking at the clinical data 
and biochemical processes that occur with the onset of inflammation and mucus hypersecretion, to 
look at these diseases and compare them to see if there was any novel mucin present and if there was 
any difference compared to normal states. A novel finding was the presence of MUC2 in some of 















The University of Cape Town Research and Ethics Committee approved this study (Ethics approval 
number REC REF: 069/2006).
2.2 Materials
Guanidine hydrochloride (GuHCl), agarose (TYPE V), urea, bovine serum albumin, caesium chloride, 
lithium perchlorate, piperazine and Poly-L-Lysine were obtained from Sigma Company, St Louis, USA. 
LumiGLO Reserve Western blot kit was purchased from KPL, Whitehead Scientific. Sodium chloride, 
dialysis tubing, sterile water and nitrobond pure nitrocellulose (0.22µm) membrane were purchased 
from Argon Laboratory Services, RSA. Beckman International supplied ULTRA CLEAR™centrifuge 
tubes (16 X 76mm). HPLC Mono Q™ 5/50 GL column (GE Healthcare, Tricorn) was supplied by 
Anatech, RSA. Ethylenediaminetetra-acetic acid disodium salt (Na2-EDTA), Tris (Hydroxymethyl) 
aminomethane, ammonium persulfate, iodoacetamide (IAA), Folins Ciocalteu’s phenol reagent, 
acrylamide, NN’-methylenebisacrylamide (Bis), ammonium persulfate (AMPS), N-ethylmaleimide 
(NEM), sodium metabisulphite, sodium dodecyl sulphate (SDS), periodic acid and 2-mercaptoethanol 
were supplied by British Drug House (BDH), Dorset, UK. Sodium carbonate anhydrous, disodium 
hydrogen orthophosphate anhydrous and sodium dihydrogen orthophosphate were from SAARCHEM 
(Merck).  
2.3 Sample Collection
Asthma and COPD sputum samples were collected from patients attending the Victoria, GF Jooste 
and Groote Schuur Hospitals, all in the region of Cape Town. The asthma and COPD patients from the 
above-mentioned hospitals were either in the Respiratory Ward, Respiratory Outpatient Clinic or in the 
Casualty Unit. ‘Normal’ sputum samples were collected from healthy volunteers in the Department 
of Surgery Research Laboratory at the University of Cape Town, from colleagues, friends and family 
members. The sputum samples were collected on ice in 50ml tubes containing 5.0ml 6M GuHCl 











2.4 Sputum induction for healthy volunteers
Sputum induction, a non‑invasive technique was used to collect samples from healthy individuals. The 
volunteers were nebulised using 3% saline for a total time of 21 minutes with three breaks (7 minutes 
per induction), using an ultrasonic nebuliser (MED active Clearway 1000, Brescia, Italy). During the 
breaks, the volunteers had to blow their noses, rinse their mouths with water and try to cough to 
produce sputum. Most of the volunteers found this process difficult and produced more saliva than 
sputum (Pin et al, 1992; Bacci et al, 2002; Bathoorn et al, 2007). 
2.5 Sputum from respiratory disease patients
A number of patients attending the above-mentioned hospitals were being nebulised for acute 
exacerbations and voluntarily gave their sputum for research, while the other patients spontaneously 
produced sputum by coughing only. In most cases, the COPD patients produced more sputum than the 
asthma patients. The asthma sufferers were exhausted after acute exacerbations and this resulted in low 
sputum production. Sputum collection was generally difficult with patients being too tired or in some 
cases too embarrassed to cough due to exacerbations, or patients being discharged before we could 
have access to them.
2.6 Solubilisation of sputum
Weighed sputum samples in 6M GuHCl were mixed overnight at 4°C to allow sputum to dissolve in 
GuHCl. The more viscous sputa samples were homogenised using, a Junkel and Kunkel Ultra-Turrax 
(40 seconds, 9500min-1, RT), to further disaggregate the sputum and increase its solubility in GuHCl. 
After sonication, the samples were centrifuged at 800g in a HITACHI, HIMAC centrifuge for 1h at 4°C 
to remove any cell debris and food particles (Allen 1977). The supernatant was stored at -20ºC until 
further purification and the pellet was discarded. 
2.7 Purification of mucins
Respiratory mucins were purified according to the method described by (Creeth and Denborough 1970). 
Briefly, mucins were extracted with 4M GuHCl containing protease inhibitors such as 10mM EDTA 
and 1mM PMSF at pH 6.5, and adjusted to a density of 1.39 to 1.40g/ml with solid caesium chloride 
(CsCl). The samples were purified by a two‑step isopycnic density gradient ultracentrifugation in CsCl, 











that fractionate at lower densities to that of mucin (Creeth and Denborough 1970; Starkey et al, 1974) 
and proteins that fractionate at higher densities to that of nucleic acid (Allen 1984). This technique has 
been established as the accepted method for the isolation and purification of mucins.
2.8 Analytical Procedures
After centrifugation, aliquots were taken from each of 8 fractions, starting from the top of the tube, 
for the determination of density by weighing (g/ml), protein content (Lowry et al, 1951) and mucin 
(glycoprotein) content by PAS method (Mantle and Allen 1978). The fractions that contained the pure 
mucin as indicated by the PAS positive peaks at a density of 1.39-1.40g/ml were pooled, dialysed 
against distilled water to remove CsCl and excess salts, lyophilized, weighed and stored at -20ºC. 
2.8.1 PAS assay
Mucin detection was performed by the PAS assay and measured at a wavelength of 555nm (Mantle 
and Allen 1978). 
2.8.2 Lowry assay
The amount of crude protein was quantitatively measured and the protein during purification was 
qualitatively measured using the LOWRY assay at a wavelength of  700nm according to Lowry et al 
(Lowry et al, 1951). 
2.9 Reduction and alkylation
Freeze‑dried purified mucin samples were reduced in 6M guanidinium chloride/0.1M Tris, pH 8.0 
containing 10mM dithiothreitol (DTT) for 5h at 37°C. After reduction, the sulphydryl groups were 
carboxymethylated with iodoacetamide (IAA) to prevent re-formation of disulphide bonds. IAA was 
added to a final concentration of 25mM and the mixture was left overnight at room temperature in the 
dark (Thornton et al, 1994). After reduction and carboxymethylation, the purified reduced mucins in 6M 
guanidinium chloride from the asthma and COPD patients were dialyzed against 6M urea for 3 days to 
remove GuHCl salts and to ensure that the sample was in the correct buffer conditions for separation by 
anion‑exchange HPLC. The samples from the normal group were reduced after purification, dialysed 
against water for 3 days, freeze‑dried to concentrate the mucin sample as the amount of purified normal 












Ion‑exchange chromatography was used to separate, identify and quantify compounds based on their 
different charge properties. Mono Q is a strong anion exchanger with a charged group (O-CH2-CHOH-
CH2-O-CH2-CHOH-CH2-N
+(CH3)3) which aids in the separation of pure reduced mucin through ion-
exchange chromatography (Morimoto et al, 1996; Handbooks and Biosciences 2004). 
Ion‑exchange chromatography is used to separate different species of purified mucins that contain 
a wide variety of negative charges due to the presence of anionic sialic acid (Allen 1984; Kirkham 
et al, 2002). MUC5AC is an acidic mucin and is therefore the first to elute using HPLC and a Mono 
Q 5/50GL column (Kirkham et al, 2002). Figure 2-1 shows the positively charged Mono Q column 
interacting with the negatively charged ions on the mucin.
Figure 2.1: Ion exchange (Handbooks and Biosciences 2004).
The separation of the mucin on the column is based on the solubility between the two liquid phases 
- the mobile or solvent phase and the stationary or bonded phase. In this case, the start buffer is 
the mobile phase and the elution buffer is the stationary phase. The 20ml loop and Mono Q 5/50GL 
column was primed for 45 minutes with the starting buffer of 10mM piperazine, pH 5.0 made up in 
6M urea containing 0.05% CHAPS before the sample was injected into the column. Each sample of 
varying concentration of mucin (as the concentration of the sample depended on the amount of sputum 











with 6M urea and before each HPLC run, was centrifuged at 800g, at 4ºC for 10 minutes to ensure the 
mucin was in solution. This 10ml mucin sample was injected into the 20ml loop through the injection 
valve and the trigger was switched to activate the run. The trigger allowed the sample to move through 
the loop and onto the column. The mucin samples were then chromatographed on the Mono Q column 
eluted with 0 to 0.4M lithium perchlorate/10mM piperazine, pH 5.0 in 6M urea containing 0.05% 
CHAPS for a 60‑minute run at a flow rate of 0.5ml/min and at a wavelength of 280nm (UV) to produce 
a linear gradient. The fractions collected were assayed with the PAS method to confirm the presence of 
mucin in the peak produced from the HPLC Mono Q column. The PAS assay, modified for the lesser 
volume (50µl) of the concentrated HPLC fractions was done using an ELISA plate and read on an 
ELISA plate reader at 540nm. This is the first time this HPLC Mono Q system has been used in our 
laboratory and is now well established.
2.10.1 Maintenance of Mono Q column
Cleaning of the column is essential as it reduces back-pressure, prevents colour change at the top of the 
column and increases sample recovery. Before and after each sample run, the column was washed with 
distilled water at the same flow rate. Regular cleaning entails changing the direction of flow so that 
contaminants do not flow the entire length of the column. The cleaning procedure of the column was 
as follows; 20 minutes with 2M NaCl, 40 minutes with 1M NaOH, another 20 minutes with 2M NaCl 
and finally a water rinse of at least 20 minutes until UV baseline is stable at a wavelength of 280nm 
and a flow rate of 0.5ml/min at RT.
2.11 Agarose gel electrophoresis
Agarose gel electrophoresis is a method that aids in the characterisation of mucin, by separating them 
according to the different charge forms (Holden et al, 1971). Loading buffer containing 1xTAE/ 50% 
glycerol /bromophenol blue was added to the mucin samples which were applied to the gel. The 
concentration of each sample loaded onto the gel varied as the amount of sample collected could 
not be controlled. The amount of positive control however was consistent throughout the study with 
a concentration of 1mg/ml loaded onto each gel. The negative control used was sample application 
buffer (SAB) containing no mucin. The mucin samples (crude mucus, purified mucin and HPLC mucin 
fractions) and the positive and negative controls, in a total of 50µl, were loaded into each of the lanes 











1xTAE buffer containing 0.1% (w/v) SDS (40mM Tris acetate, 1mM EDTA, pH 8.0, containing 0.1% 
(w/v) SDS). The positive control used was PMP which is positive for MUC5AC, MUC5B and MUC2. 
On completion of electrophoresis, the gels were soaked in 0.6M sodium chloride/0.06M sodium citrate 
(4xSSC) or transfer buffer to remove excess tank buffer (1xTAE) and prepare the gel for vacuum 
blotting. By soaking the gel in 4xSSC, the gel is prevented from swelling during the vacuum blotting 
procedure. Variable amounts of sputa were collected and therefore this study depended on volume 
rather than quantity which was  shown not to matter by Henke et al as volume equivalents could be 
used (Henke et al, 2004).
2.12 Western blot analysis
Western blot or immunoblot is a method used to identify and detect the presence of specific proteins 
in a sample. Mucins in the respiratory tract were identified and detected with the aid of antibodies 
specific to the lung (Rose and Voynow 2006). Nitrocellulose membranes with the pore size of 0.2µm 
were soaked in tank buffer until the membrane changed colour (white to colourless) or until the 
membrane was wet (approximately 5 minutes) (Thornton et al, 1989). The membrane was then placed 
on the vacuum blot apparatus and before applying the gel, 4xSSC containing 10% poly-L-lysine was 
vacuum blotted onto the membrane to ensure that the protein from the gel binds to the membrane 
via electrostatic interactions (Thornton et al, 1989). The gel was carefully placed on the membrane, 
ensuring that there were no air bubbles between the gel and the membrane as this would interfere with 
the transfer of protein and disrupt the western blot analysis. The gel was vacuum blotted for 2h at 
40mbars and kept wet with 4xSSC to ensure complete transfer of proteins. After vacuum blotting the 
nitrocellulose membrane was washed with distilled water for 5 minutes and then incubated in blocking 
buffer (1% fat free milk powder in TBST) for 1h at RT, on the shaker. The blocking buffer was removed 
and the membrane was incubated in primary antibody for 2h at RT on the shaker or overnight at 4ºC. 
All primary and secondary antibodies were diluted in TBST.  The membrane was washed 3 times for 
5 minutes with 1xTBST (washing solution) to ensure removal of excess unbound primary antibody 
and then incubated with secondary antibody for 1h at RT on a shaker. The excess unbound secondary 
antibody was removed with three 10-minute washes of 1xTBST to ensure the membrane is free of any 












In this study, antibodies to the major respiratory mucins found in the lung were used namely, MUC5AC 
(Hovenberg et al, 1996) and MUC5B (Thornton et al, 1994; Wickstrom et al, 1998). The Thornton 
group in Manchester kindly donated the MUC5AC and MUC5B antibodies. MUC5AC and MUC5B 
polyclonal rabbit antibodies were raised against a synthetic peptide that recognises specific sequences 
as seen in Table 2-1 under antigen recognition. The MUC2 polyclonal antibody that recognises the 
non-tandem region of the C-terminus was kindly donated by Professor D. Swallow, Department of 
Biology, University College London (Herrmann et al, 1999). 
This mucin gene was found to have low levels of expression in the respiratory tract (Herrmann et al, 
1999; Thornton et al, 2007). The secondary antibody a polyclonal goat anti-rabbit immunoglobulin/
HRP was purchased from DakoCytomation.
Table 2-1: Primary and secondary antibodies used in western blot analysis.
Primary antibodies
Antibody type Antigen Dilutions
Polyclonal rabbit anti-
MUC5AC/LUM5-1
A synthetic peptide RNQDQGPKFMC
(Hovenberg et al, 1996)




RNREQUGKFKMC, NH2 terminus of the 
MUC5B apomucin (Wickstrom et al, 1998)




NGLQPVRVEDPDGC, non-tandem repeat 
region of the C-terminus (Herrmann et al, 1999)
1: 2000 (2h at RT or 
O/N at 4ºC)
Secondary antibodies
polyclonal goat anti-rabbit immunoglobulin/HRP 1: 20000 (1h at RT)
2.12.1 Chemiluminescence
Enhanced chemiluminescence detection (ECL) was used to visualise the immunoreactivity between 
the antibodies and the mucin. ECL is a good detection method as it can detect femtomole quantities of 
mucin. After completion of the western blot analysis, the membrane was stored in distilled water until 
detection with chemiluminescence and visualisation by autoradiography using an X-ray machine or a 













Once detection with the first primary antibody was complete, the membranes were incubated with 
stripping buffer (2% SDS, 100mM mercaptoethanol, 0.5M NaCl and 62.5mM Tris-HCl buffer at pH 
6.7) for 1hour at 37ºC. The membranes were then washed twice for 10 minutes with distilled water 
and then incubated in 1xTBST for a further 10 minutes. The membranes were washed for another 10 
minutes with distilled water to ensure that they were free of stripping buffer. Once the membranes 
were clean, they were incubated in blocking buffer for 1 hour on the shaker and then probed for the 
next primary antibody of interest (Henke et al, 2004; Femmeauburn 2005). Stripping was a cost-
effective and time-saving method that was previously conducted in our laboratory by Govender, 2006 
and worked effectively (Govender 2006). 
2.13 Amino acid analysis
The amino acid content of purified respiratory mucins was analysed using a high pressure liquid 
chromatography (HPLC) system according to the methods of Klapper (1982). In this method samples 
were vacuum-dried and placed in a hydrolysis vessel containing constant boiling HCl and 1% (v/v) 
phenol before hydrolysing in the gas phase at 110ºC for 24h. The vessel was purged with nitrogen gas 
and sealed under vacuum. The vials were cooled and vacuum dried to remove the residual HCl. The 
dried samples were solubilised in citrate buffer pH 2.2 and injected into a HPLC column from Waters 
Associates, Medford, MA., filled with cation exchange resin (sulfonated polystyrene cross‑linked with 
divinylbenzene) and eluted with a number of buffers ranging from a low (0.25M trisodium citrate, 
pH 3.05) to high (0.25M sodium nitrate, pH 9.5) pH. Detection of amino acids was performed using 
post column derivatization with O‑phthalaldehyde (OPA), a fluorescent reagent that interacts with all 
the amino acids except proline. For proline detection, treatment of samples with sodium hypochlorite 
ahead of post column derivatization with OPA was required (Klapper 1982). The relative ratios of 
the individual amino acids for each sample were determined and compared to each other. Jeronimo 













Patients’ clinical details and sample collection for 
further biochemical analysis
3.1 Introduction
The biochemical characterisation of mucus and mucins in respiratory diseases namely, asthma and 
COPD, were analysed using anion-exchange chromatography and western blot detection methods. 
Mucins were isolated from the sputum samples collected in 6M GuHCl containing proteolytic inhibitors 
(EDTA and PMSF) using isopycnic density gradient centrifugation in CsCl, reduced with10mM DTT, 
and subsequently alkylated with 25mM IAA. Reduction and alkylation exposes the mucin epitopes for 
detection by Western blot analysis (Thornton et al, 1995).  This work has been approved by the UCT 
Human Ethics Committee (see Chapter 2 for REC/REF number).
Table 3‑1, 3‑2 and 3‑3 show quantitatively the amount of sputum collected in 6M GuHCl from the 
healthy volunteers and the patients suffering from respiratory diseases namely, asthma and COPD 
before purification and the amount of dry‑weight mucin extracted from the sputum after purification. 











3.2 Data of sputum from healthy individuals 
Sputum induction was conducted using 3% saline to aid in the expectoration of sputum from the 
lower airways of healthy volunteers (Bacci et al, 2002). This method was effective but required the 
participation of the volunteers. The amount of sputum collected varied from individual to individual 
as some had their airways irritated easier than others. Table 3-1 shows the varying amounts of sputum 
collected. This influenced the amount of purified mucin obtained for my investigations.











mg Mucin/mg  
Wet Weight
N1 F 55 20.0616 11.03 8.2 0.41
N3 F 33 7.9945 9.30 4.5 0.56
N4 F 30 12.8532 11.30 3.9 0.30
N5 F 24 3.7230 3.50 2.7 0.73
N6 F 26 3.0166 3.10 2.3 0.76
N7 M 61 2.1523 5.90 8.6 3.99
N8 M 27 8.5810 10.50 1.4 0.61
N9 M 21 6.2260 3.96 10.8 1.73
N12 M 28 1.4609 2.01 20.8 14.23
N14 M 38 1.8820 2.40 0.8 0.43
To date there is only one volunteer who currently smokes (N9), two ex-smokers (N7 who last smoked 
30 years ago and N12 who last smoked 10 years ago) and the remaining volunteers who have never 
smoked. There are an equal number of males and females and the ages range from 21 to 61years. 
Interestingly the mucin concentration of the current smoker (N9) and of the ex-smoker (N12) is higher 












3.3 Data of sputum samples from asthma patients
Sputum was collected from asthma patients being treated (nebulised) for an acute asthma attack. 
Table 3-2: Sputum from respiratory disease patients suffering from asthma.














37 Victoria F 34 1.7405 0.199 1.16 0.67
38 Victoria M 57 1.2173 0.192 1.24 1.02
39 Victoria M 44 2.5398 0.327 7.24 28.50
40 Victoria M 51 2.3477 0.185 1.23 0.52
41 Victoria F 47 7.1372 0.283 6.32 0.88
42 Victoria F 74 2.4464 0.192 1.08 0.44
43 Victoria F 50 3.6559 0.204 1.14 0.31
44 Victoria M 40 1.4564 0.199 0.80 0.55
45 Victoria M 72 13.429 0.386 19.72 1.47
46 Victoria F 51 0.7483 0.219 1.25 1.67
47 Victoria M 73 0 0.189 0.80 0
52 GSH F 55 2.8504 0.259 4.90 1.42
54 GSH M 50 1.0401 0.705 11.51 11.07
56 GSH F 73 4.9952 0.200 5.80 1.16
57 GSH M 62 3.3718 0.460 3.52 1.04
There were adults only in this group. The ages ranged from 34 to 74 years. The majority of patients 
were from Victoria Hospital and there were more females than males in this group.
There was only one confirmed smoker in this group, patient (A42) and the rest are unknown.











3.4 Data of sputum samples from COPD patients
Sputum was collected from COPD patients being treated (nebulised) for an acute respiratory attack. 
 
Table 3-3: Sputum from respiratory disease patients suffering from COPD.














8 Victoria M 54 5.3683 N/A N/A N/A
27 Victoria M 56 14.277 0.448 0.05 0.003
28 Victoria F 43 1.2363 0.216 2.31 1.72
29 Victoria M 37 1.0433 0.271 1.52 1.46
31 Jooste M 75 2.8474 0.443 1.04 0.36
36 Jooste M 74 0.2795 0.207 1.94 6.95
48 GSH F 44 9.7970 0.355 25.90 2.64
50 GSH M 52 10.542 0.428 9.30 0.88
51 GSH M 58 2.2878 0.173 6.50 2.84
53 GSH F 59 4.8816 0.123 3.60 0.74
55 GSH F 34 3.3825 0.109 6.60 1.95
58 GSH M 82 1.1830 0.114 3.90 3.30
59 GSH F 35 6.2107 0.060 1.00 0.16
61 GSH M 87 1.0173 4.000 2.10 2.06
62 GSH M 63 3.6006 7.400 7.80 2.17
There were adults only in this group. The ages ranged from 34 to 87 years. The majority of patients 
were from GSH in Observatory and there were more males than females in this group. There were 
only 7 confirmed smokers in this group, patients’ (C29, C36, C48, C51, C55, C61 and C62), and 1 











3.5 Clinical Data of patients with disease
Clinical data for patients with asthma and COPD was obtained from second tier hospitals Victoria and 
G.F. Jooste and GSH a tertiary hospital and teaching institution. These three hospitals serve patients 
from a huge community of people who come from poor socio-economic backgrounds and who live 
in sandy low-lying areas commonly known as the “Cape Flats”. The predominant group living on the 
“Cape Flats” was previously classified as “Cape Coloured” because of their ethnic ancestry (African 
and Asian). The sample for this study was drawn from South African adult males and females.
3.5.1 Methods of collecting sputum from patients with disease
Visits and telephone calls were made to these hospitals to find patients, suffering from asthma and 
COPD, that had been admitted due to an acute respiratory attack or respiratory distress. The attending 
physician made the medical diagnosis of either asthma or COPD. The patients were asked to read 
and sign a consent form, shown in the appendix A and B. The procedure for producing sputum was 
explained to the patients who were asked to cough to try to produce sputum from the lungs. 
3.5.2 Complicating factors relating to sputum collection
Whilst the majority of patients expectorated unaided to provide us with sputum, a certain number of 
patients and most of the volunteers had to undergo sputum inductions in order to produce some sample. 
Many patients tried to co-operate but due to the fact that they were not feeling well and/or were being 
discharged refused to cough again. This resulted in small volumes of sample. 
3.5.3 Reasons for patient admission
The patients suffering from respiratory diseases on admission to the hospital, presented with a productive 
cough, wheezing, chest pain or acute exacerbations. Their sputum colour changed from clear to either 
white, yellow or in some cases green, which are indicators of chest infection. The patients’ folders and 
the attending physicians provided us with this information (personal communication with the attending 
physicians).
3.5.4 Information of patients with disease
The following information was retrieved from the patients’ folders. Most patients were on the same 











folders was limited and we could only confirm that there were 7 smokers and 1 non‑smoker in the COPD 
group and 1 smoker in the asthma group. The information regarding the other patients is unknown. 
Besides suffering from asthma and COPD, these patients had other ailments such as hypertension and 
dyspnoea. Three patients died during this study and one patient’s disease progressed from asthma to 
COPD. 
3.6 Discussion
The macroscopic observation of the crude sputa collected from the patients with asthma and COPD 
appears to be infected due to the difference in the colour (yellow and green) as compared to the sputa 
collected from the healthy volunteers (N) that remained clear. More purified mucin was extracted from 
the sputa collected from the asthma and COPD patients than from the normal volunteers which could 
be due to the infected crude sputa produced. According to the literature there is an up-regulation of 
mucins in diseased airways as compared to healthy airways (Thornton et al, 2007) as was observed 
in this study. The mucin concentration was greater in the COPD group compared to the asthma and 
normal groups. The normal group had the least mucin concentration as mucins are not up-regulated in 












Extraction, purification and isolation of 
mucins from human airways
4.1 Introduction
Sputum samples were collected from healthy volunteers (no known respiratory disease) and patients 
suffering from respiratory diseases namely, asthma and COPD. Sputum containing DNA, lipids, 
proteins and mucin, was suspended in 6M GuHCl containing proteolytic inhibitors (EDTA and PMSF). 
Isopycnic density gradient centrifugation was used to isolate mucins (Carlstedt et al, 1983). The mucins 
were extracted from the soluble sputa by a two-step caesium chloride isopycnic density gradient 
centrifugation at a buoyant density of between 1.39 - 1.40g/ml to remove all contaminants (DNA, lipids 
and proteins) and isolate the mucins. After two successive equilibrium density gradient centrifugations, 
each for 48h at 105 000g in a Beckman ultracentrifuge, mucins were collected by fractionation of the 
CsCl density gradient, from the top of the tube. The density of each fraction was measured, the PAS 
assay method was used to detect glycoproteins (Mantle and Allen 1978) and the Lowry method for the 
detection of proteins (Lowry et al, 1951). The PAS positive fractions containing the glycoproteins were 
pooled and dialysed overnight against distilled water to remove CsCl and GuHCl. After dialysis, the 
pure mucin was lyophilised and the dry weight of mucin (w/w) was calculated.
Anion‑exchange chromatography is an analytical technique that separates molecules based on charge. 
Purified mucins, reduced with DTT and carboxymethylated with IAA, were chromatographed on a 
Mono Q 5/50GL column eluted with a linear gradient of 0–0.4M lithium perchlorate, 10mM piperazine, 
pH 5.0, in 6M Urea containing 0.05% 3-[(cholamidopropyl)dimethylammonio]-1-propanesulfonate 
(CHAPS) (elution buffer) (Kirkham et al, 2002). 
The Mono Q column is positively charged and binds to the negatively charged mucins, which are 
eluted from the column with lithium perchlorate in the elution buffer. Purified reduced mucins from 
normal, asthma and COPD samples were separated by anion-exchange HPLC on a Mono Q column 













Figure 4.1 illustrates the PAS, protein and density profile of the respiratory mucins in normal, asthma 
and COPD patients after the first and second CsCl centrifugation steps. Absorbance measurements 
at 700nm suggested the presence of trace amounts of protein under the mucin peak (Figure 4.1) and 
therefore the mucin containing peaks (Figure 4.1, fractions 3, 4 and 5, left panel) were pooled and 
subjected to a second CsCl centrifugation to separate the mucins (1.39-1.40g/ml) from the protein. 
Figure 4.1, right panel illustrates that the mucins are free of protein contaminants after the second 
centrifugation step. The PAS peak at a density of (1.39-1.40g/ml) showed the mucins to be pure (Figure 
4.1, fractions 4-6, right panel). 
4.2.2 HPLC analysis
Purified reduced respiratory mucin samples were made up in 10 ml of 6M urea and loaded onto the 
Mono Q column which separates mucins based on charge. Figure 4.2 (left panel) shows the mucins 
from normal, asthma and COPD patients eluting as a broad peak from the Mono Q column. Aliquots of 
these fractions were analysed for the presence of mucin using the PAS assay (Mantle and Allen 1978; 
Kirkham et al, 2002) and the PAS positive fractions were further analysed to identify the presence of 
the respiratory mucins.  Figure 4.2, left panel is an HPLC profile and Figure 4.2, right panel is a PAS 
profile of the eluted fractions from the HPLC column of all 3 groups. The PAS profile (Figure 4.2, right 
panel) shows the presence of mucins in all 3 groups. The PAS positive fractions were further analysed 
by Western blot technique for the presence of MUC5AC, MUC5B and MUC2. 
4.3 Discussion
4.3.1 CsCl centrifugation purification 
Mucus was solubilised in a mixture of 6M GuHCl containing proteolytic inhibitors (EDTA and PMSF) 
in order to minimize enzymatic degradation through endogenous proteolysis during the course of the 
experiments (Sheehan and Carlstedt 1984). GuHCl is a chaotropic agent that prevents mucin association 
by disrupting the structure of water and suppressing ionic and hydrogen-bonding interactions (Sheehan 
and Carlstedt 1984; Bromberg and Barr 2000). It also removes protein contamination, denatures 
proteins and suppresses the activity of the degradative enzymes (Carlstedt et al, 1983). The proteolytic 











(Carlstedt et al, 1983; Sheehan and Carlstedt 1984). 
Isolation and purification by isopycnic density centrifugation in CsCl is a known method to successfully 
separate mucins from lower density lipids and proteins and higher density nucleic acids (Creeth and 
Denborough 1970; Creeth et al, 1977; Carlstedt et al, 1983). CsCl density gradients isolate the mucin 
at a density of 1.4g/ml and are compatible with the collection mixture of GuHCl and proteolytic 
inhibitors. CsCl dissociates non-covalently bound protein-glycoprotein interactions (Starkey et al, 
1974). This method is important as it aids in the understanding of the structure-function relationship 
of mucins (Woodward et al, 1982) and is the accepted method to use when analysing mucins (Allen 
1981). CsCl purification is a laborious practice that involves lengthy intermediate steps which require 
large quantities of reagents and involves two and sometimes even three ultracentrifugation steps for 
48hr each. All samples were purified by the method of density gradient centrifugation in CsCl to 
extract and analyse the respiratory mucins. The removal of protein contaminants after CsCl density 
gradient ultracentrifugation was evident. SDS‑PAGE analysis of purified mucin was conducted to test 
the purity of the mucin and to ensure the absence of protein contamination with Brilliant Coomassie 
Blue staining (not shown).
Mucin samples after purification were dialysed, lyophilised and then reduced with 10mM DTT and 
subsequently alkylated with 25mM IAA. DTT is a reducing agent that breaks intermolecular and 
intramolecular disulphide bonds between cysteine residues of the glycoprotein, promotes unfolding of 
the peptide chain and aids mucins in forming subunits (Holden et al, 1971; Rose et al, 1979; Carlstedt 
et al, 1983). Iodoacetamide (IAA) is an alkylating agent that prevents mucin aggregation and keeps 
the molecule in a subunit form by binding covalently with cysteine, so the protein cannot aggregate to 
its natural polymeric form (Rose et al, 1979). Reduction and alkylation was carried out on the purified 
mucin samples to generate mucin subunits (Holden et al, 1971; Pearson et al, 1981; Thornton et al, 
1995). Reduced mucin subunits, smaller in size and less viscous can be injected into the HPLC column 
for detection and analyses. Bronchial mucus needs to be reduced as it is very viscous and forms gels 
very easily (Houdret et al, 1981). Reduction is also important in antibody detection as it exposes the 
mucin epitopes for detection and interaction between mucin and antibody during western blot analysis 
(Thornton et al, 1995). These biochemical methods are important in the investigation of mucins found 












Mono Q is a strong anion exchanger with a positively charged group that binds easily to the negatively 
charged mucins that are eluted with lithium perchlorate (LiCLO4), which is a positively charged salt. 
The column and the salt compete to bind the mucin aiding in the elution of the mucin from the column. 
The purified reduced respiratory mucins from normal, asthma and COPD samples were solubilised in 
6M urea and then subjected to ion-exchange chromatography (HPLC) using a Mono Q 5/50GL column. 
The mucins were eluted from the Mono Q column with a linear gradient of 0-0.4M lithium perchlorate 
(Thornton et al, 1996) for 60 minutes (Davies et al, 1996), (Dr Sara Kirkham from the University of 
Manchester, personal communication). We adapted the technique described by Thornton et al (1996) 
with some modifications. The modifications were the size of the loop (20ml), the extra tubing attached 
from the detector to the fraction collector and the time the fractions were collected (96 minutes). 
We loaded 10ml of purified reduced mucin sample onto the Mono Q column through a 20 ml loop. 
The amount of sample loaded onto the column depended on the amount of sputum collected from 
the patients and volunteers. The concentrations ranged from approximately 0.01mg/ml to 20mg/ml 
(Chapter 3 Tables 3.1, 3.2 and 3.3). The mucin fractions (0.5ml/min) eluted as seen on the HPLC 
profile (Figure 4.2, left panel). The PAS profile (Figure 4.2, right panel) confirms the presence of mucin 
as indicated by the peak. This HPLC profile was different to that of Thornton et al (1996) very likely 
due to the modified method used in this study. The mucin was chromatographed for 96 minutes. A 96 
well plate was used for the detection of the mucin in the fractions eluted from the Mono Q column 
using the PAS assay, and the absorbance was read at 540nm in an ELISA plate reader. 
A limitation of this study was that the HPLC technique was not available in this laboratory and had to 
be established from the beginning with much troubleshooting, which was time-consuming and very 
costly. We were able to set up this modified HPLC system through personal communication with Dr 
Sara Kirkham from the University of Manchester.
Once the mucins from the normal, asthma and COPD samples were extracted, purified and isolated 
by CsCl density gradient ultracentrifugation and HPLC Mono Q column analysis, the purified reduced 


















Figure 4-1: First (panel on the left) and second (panel on the right) caesium chloride isopycnic
density gradient purification of normal (A, B), asthma (C, D) and COPD (E, F) sample. 
Figure 4-1: First (panel on the left) and second (panel on the right) caesium chloride isopycnic 










A PAS, protein and density profile of the first and second CsCl purification of respiratory mucus. The 
density of each fraction was measured (▲), following dialysis of aliquots of mucus samples against 
distilled water, each fraction was analysed for glycoproteins (■) PAS and protein (♦) Lowry. The results 
are expressed in absorbance values (PAS at 555nm and protein at 700nm) and density in g/ml.
(A) Mucin sample from a normal healthy volunteer after the first centrifugation step with CsCl.
(B) Mucin sample from a normal healthy volunteer after the second centrifugation step in CsCl.
(C) Mucin sample from an asthma patient after the first centrifugation step in CsCl.
(D) Mucin sample from an asthma patient after the second centrifugation step in CsCl.
(E) Mucin sample from a COPD patient after the first centrifugation step in CsCl.



















































Figure 4-2: Mono Q elution (panel on the left) and PAS (panel on the right) profiles of reduced/










The graphs represent a mucin elution profile from the Mono Q 5/50GL column with 0.4M lithium 
perchlorate in the eluting buffer. Reduced mucin subunits were chromatographed on a Mono Q 5/50GL 
column. Lithium perchlorate concentration rises linearly from 0 to 0.4M in 60 minutes and then back to 
0M in 5 minutes. Many Mono Q fractions contain more than one mucin species. Fractions eluted from 
the Mono Q column had similar charge densities for each group. Quantitative comparison between 
each Mono Q mucin elution profile is not possible.
(A) HPLC profile of a mucin sample from a normal healthy volunteer.
(B) PAS profile of a mucin sample from a normal healthy volunteer.
(C) HPLC profile of a mucin sample from an asthma patient.
(D) PAS profile of a mucin sample from an asthma patient.
(E) HPLC profile of a mucin sample from a COPD patient.












Identification of respiratory mucins in airways normal subjects 
(N) with no diagnosed disease by Western Blotting
5.1 Identification of mucins by Western Blotting
The objective of the study reported in this chapter was to characterise the mucins in the sputa of airways 
of normal individuals by Western blotting. Crude sputa from 10 ‘healthy’ (symptom-free) volunteers 
(N) were collected after sputum induction and solubilized in cold 4M GuHCl and proteolytic inhibitors. 
The disulphide bonds of the mucins were then reduced with 10mM DTT and subsequently alkylated 
with 25mM IAA, to obtain mucin subunits with epitopes exposed for detection (Kirkham et al, 2002). 
Mucins were purified by density gradient centrifugation in CsCl, after which they were analyzed by 
HPLC analysis on a Mono Q 5/50GL column using a modified method of Thornton et al, (1996). Mucin 
identification was by agarose gel electrophoresis and Western blotting, again a slight modification of 
the method of Thornton et al, (1996) and developed in our laboratory (Trimmel et al 2008, in press). 
5.2 Results
Western blot analysis was performed to determine the identity of the mucins present in normal 
airways. Samples were loaded onto a 1% agarose gel and subjected to electrophoresis. Mucins were 
then transferred from the gel onto a nitrocellulose membrane by vacuum blotting and probed with 
polyclonal anti-sera that recognise protein epitopes on the VNTR region of MUC5AC, MUC5B and 
MUC2 (Chapter 2, Table 2-1), shown in the blots (Figures 5.1, 5.2 and 5.3), respectively. The same 
volume of material was loaded on all gels. Western blotting confirmed the presence of MUC5AC and 
MUC5B in normal airways although the amounts of MUC5B were far less on the gel (Figure 5.2) than 
MUC5AC (Figure 5.1), albeit for equal volumes of material. Surprisingly some of the normal sputa 
showed varying amounts of MUC2 (Figure 5.3), again for equal volumes. 
The  specificity of the MUC5AC antibody LUM 5‑1, in the blots of samples from volunteers (N) (Figure 
5.1) was confirmed against a purified sample of PMP (Figure 5.1 A‑F, lanes 1). This appeared as a very 
large smear of material from the top of the gel to quite far down. Crude and untreated sputa samples 
from the normal subjects gave varying amounts of MUC5AC  in  the gels (Figure 5.1 A-F, lanes 2) 











being reduced with DTT and loaded on the gel (Figure 5.1 A-F lanes 3), ran in approximately the same 
position as the purified and reduced samples eluted from the Mono Q column. The eluted fractions 
from the Mono Q column showed a slight charge gradient (Figure 5.1 A-F, lanes 4-11), more apparent 
in some cases (Figure 5.1 B and D, lanes 4-11) than in others (Figure 5.1, A, C, E and F).  Sample 
application buffer was loaded in lanes 12 (Figure 5.1 A-F) and used as the negative control. 
The presence of MUC5B (Figure 5.2) in the normal secretions was much less when compared to 
MUC5AC (Figure 5.1) and only found in 5 out of 10 secretions of the volunteers (N). The volunteers 
(N) that had MUC5B present (Figure 5.2 A-C), had lower levels of this mucin compared to MUC5AC 
for equal volumes of material loaded onto the gel (Figure 5.1 A‑F). MUC5B was present in the positive 
(PMP) control in lanes 1 (Figure 5.2 A-C, arrows). A sample of crude sputa appeared as a band in the 
gel (Figure 5.2 A, lane 2), as a band just entering the gel (Figure 5.2 B, lane 2, arrow) and was absent 
from the gel (Figure 5.2 C, lane 2). A purified reduced sample of the same sputa, in lanes 3, was loaded 
onto the gel and electrophoresed as a single band (Figure 5.2 A), as a smear (Figure 5.2 B) and very 
interestingly, absent from the gel as shown in the blot (Figure 5.2 C), an indication of variation within 
a group. The purified reduced samples in lane 3 (Figure 5.2 A) electrophoresed in a similar position to 
the fractions eluted from the Mono Q column in lanes 9-11 (Figure 5.2 A) but differently to lanes 5-8 
(Figure 5.2 A, arrows), which appeared earlier. The eluted fractions (Figure 5.2 B, arrows) from the 
Mono Q column in lanes 7‑8 electrophoresed in a similar position to the purified reduced sample in 
lane 3 but differently to the eluted fractions in lanes 4-6. The eluted fractions from the Mono Q column 
showed a clear charge gradient for MUC5B (Figure 5.2 A and B, lanes 4-11). This gradient is similar to 
what was observed by Thornton et al (1996) when they looked at asthmatic reduced mucin (Thornton 
et al, 1996).
Sputa from normal controls were probed with the MUC2 antibody, LUM2-3 (Herrmann et al, 1999) 
on Western blots. MUC2 was present in only 3 out of the 10 volunteers (N). MUC2 was present in the 
positive control and appeared as a faint band (Figure 5.3 A, lane 1, as indicated by the arrow) but was 
absent in the sample. MUC2 was observed as a darker smear-band in lanes 1 (Figure 5.3 B-D, arrows) 
but this could be due to the over‑exposure of these membranes which was required in order to visualise 
the bands in lanes 2-11. Interestingly, MUC2 in the crude sputa appeared as a band in the blot (Figure 











be present but cannot be seen because it is over-shadowed by the big smear of the positive control in 
lane 1. Interestingly, the purified reduced sample (Figure 5.3 B‑D, lanes 3, arrows), electrophoresed 
similarly in all 3 gels as a distinct band indicating that the material could be highly charged because of 
its position towards the bottom of the gel. However, only sample N12 (Figure 5.3 C) in the group of 
normal volunteers had detectable MUC2 in the fractions that eluted from the HPLC.
5.3 Discussion
A defining feature of this entire study was the inter‑individual variation of mucins from controls and 
patients within each group, rather than differences between groups. This is quite different from previous 
findings of Kirkham et al, (2002) who reported, for example, a difference in MUC5AC and MUC5B 
between healthy and diseased airways. An example of this would be the absence of MUC5B, a major 
respiratory mucin in 5 of the 10 normal volunteers used in this study (see Figure 5.2 C). In some 
instances crude sputum and even purified mucin from the crude sputum from one individual reacted 
with the antibody of MUC5B whilst another did not (see Figure 5.2 A-C). The occurrence of MUC2 
in some of the controls is also an example of inter-individual variation within groups in this study (see 
Figure 5.3). 
A major limitation of this study was the different amounts of sputa obtained from each patient. This in 
some cases was so little, that mucin purification was done with difficulty and because the final yield of 
purified mucin was so little in these instances, it made loading of equivalent amounts on the HPLC and 
on gels quite impossible. However, we tried to maintain some consistency by loading, as far as possible, 
equal volumes (50μl) of material on the gels. We thus had to resort to the loading of equal volumes of 
material on the HPLC Mono Q column and gels and characterise the mucins thereof. This qualitative 
approach to mucin characterization has been reported previously (Thornton et al, 1996; Govender 
et al, 2005; Govender 2006).  Henke (2004) conducted a study on cystic fibrosis secretions where 
samples were loaded onto gels at either, the same concentration or the same volume and found that the 
intensity of the detected bands for MUC5AC and MUC5B were similar in appearance. This suggests 
that the intensity of the mucin smear-bands is not directly related to the concentration of the sample 
loaded onto a gel. The intensity of the bands in this study is related to the positive control (PMP) used 
throughout the study which was loaded at a standard concentration of 1mg/ml. It is hypothesised that a 











Appropriate positive and negative controls were used for the specific mucins on each gel. Material 
obtained from a patient with pseudomyxoma peritoneii (PMP) was used as a positive control (Figures 
5.1, 5.2 and 5.3, lanes 1) for MUC5AC, MUC5B and MUC2 in each gel (O’Connell et al, 2002; 
O’Connell et al, 2002; Mall et al, 2007). PMP is an exudative disease that originates either in the 
appendix or ovary, resulting in an accumulation of viscous fluid in the abdomen. The mucins in this 
fluid were characterised in our laboratory (Mall et al, 2007). The presence of MUC5AC, MUC5B and 
MUC2 electrophoresed as smears on an agarose gel/western blot (Mall et al, 2007). Using the same 
extraction and purification methods as in this study, we found the mucins from a patient with PMP 
very difficult to purify because of the high protein content of the viscous fluid. However, we thought 
it would make a suitable positive control for all the mucins we examined in this study. Also, after 
detection of a specific antibody, membranes were stripped in stripping buffer (see Chapter 2) to detect 
the next antibody. Therefore, for our purpose it was convenient to use the same positive control. In 
this study sample application buffer was used as a negative control in all blots. The crude, unpurified 
non-reduced mucus with a higher molecular weight electrophoresed slower than the reduced samples 
and did not completely enter the gel due to its size. The purified reduced mucin shown in lanes 3 of all 
blots, was loaded onto the HPLC Mono Q column, which separates and elutes the fractions according 
to charge (Figure 5.1 A-F, lanes 4-11).
MUC5AC is a known mucin component in gastric mucus secretions (Ho et al, 1993; Pinto-de-Sousa 
et al, 2004). MUC5AC was clearly present in the induced sputum of the ‘healthy’ volunteers in all the 
samples (10/10) (Figure 5.1 A-F, lanes 2-11). The elution of MUC5AC from the Mono Q column was 
similar to that reported by Kirkham et al, (2002) and quite in contrast to that of Govender (2006) who 
showed little or no MUC5AC in controls. Other researchers had a similar experience as Govender 
(John Sheehan, personal communication). The antibody LUM5-1 used to probe MUC5AC in this study 
was similar to previous studies (Govender 2006).
MUC5AC appeared as a dark smear-band with a clear charge separation between the fractions eluted 
from the Mono Q column for sputa collected from each of the ‘healthy’ volunteers (N) (Figure 5.1 
A‑F), with a strong signal for purified mucin from a patient with pseudomyxoma peritonei (PMP) 
used as a positive control (Figure 5.1 A-F). The position and appearance of MUC5AC on the western 











MUC5AC was found to be the major respiratory mucin in the normal secretions and which was 
confirmed in this study (10/10) in the normal healthy volunteers.
MUC5B is present in smaller amounts in the normal airways (Figure 5.2 A-C) despite it being a major 
respiratory mucin (Thornton et al, 1997). The charge separation of MUC5B between fractions eluted 
(lanes 4-11) from the Mono Q column of N7 (Figure 5.2 A) and N12 (Figure 5.2 B) is more distinct 
than that for MUC5AC. The elution profile for MUC5B showed variation with some samples showing 
eluted fractions as a clear gradient when eluted from the Mono Q column (Figure 5.2 A and B), whilst 
others had no detectable eluted material (see Figure 5.2 C). The MUC5B blots that showed a charge 
gradient (Figure 5.2 A and B) could be suggestive of the presence of MUC5B glycoforms (Kirkham et 
al, 2002). MUC5B was present in 5 out of the 10 normal sputa collected.
Figure 5.3 A-D show the results for MUC2, an intestinal mucin that has been reported to be present 
only in small amounts in the respiratory tract of diseased patients (Davies et al, 1999). The presence 
of MUC2 in normals, though controversial and shown to appear in very small amounts (Davies et al, 
1999), is largely accepted to be absent in normals by the major researchers in this field (Hovenberg et 
al, 1996). MUC2 was present in the positive control (PMP) (Figure 5.3 A–D, lanes 1 as indicated by 
the arrows). MUC2 was not detected in N7 (Figure 5.3 A) and was present in purified reduced mucin 
in lanes 3 of N9 (Figure 5.3 B), N12 (Figure 5.3 C) and N14 (Figure 5.3 D). However, the only sample 
that had detectable amounts of MUC2 in the fractions eluted from the HPLC Mono Q column was in 
N12 (Figure 5.3 C, lanes 4-11).  
Upon further investigation (after these experiments were completed) we discovered some interesting 
information about the individuals who kindly donated their sputa for this study in this group of controls. 
Control number N7 is a 61-year old male who is an ex-smoker who had MUC5AC (Figure 5.1 C), 
MUC5B (Figure 5.2 A) and no MUC2 (Figure 5.3 A). Control number N9 is a 21 year old male who is a 
current smoker and suffers from allergies. He had MUC5AC (Figure 5.1 D), MUC5B (not shown) and 
though he had MUC2 (which was purified) (Figure 5.3 B), there were no detectable amounts of MUC2 
that eluted from the HPLC Mono Q column. This could be due to technical problems or it is possible 
that the mucins ran off the gel. Control number N12 was the most interesting individual in this group. 











MUC5AC (Figure 5.1 E), MUC5B (Figure 5.2 B) and MUC2 (Figure 5.3 C), present in clear quantities. 
Even more interesting was the location of the bands at the bottom of the gel. This was comparable to 
the finding of Govender (2006), in whose study TB samples gave a similar electrophoretic profile (see 
Figure 5.4, lanes 7 and 9 as indicated by the arrows). It must be noted that Govender’s study (2006) did 
not include elution of mucin from an HPLC column. The mucins were not even purified and only crude 
samples were used. However, the location and position of the bands of individual N12, who lives with 
an ex-TB sufferer and that of the sputa of the patients used by Govender in her study, were very similar. 
The confidential nature of this study does not allow us to reveal this finding directly to the patient but 
we are discussing with the University of Cape Town Ethics Committee the possibility of divulging this 
information to the doctor of individual N12.
Also of interest was control number N14. This is a 38-year old male who never smoked, has allergies 
and according to his physician, is susceptible to asthma and eczema. He had detectable amounts of 
MUC5AC (Figure 5.1 F), no MUC5B (Figure 5.2 C) but had some purified MUC2, but too little to 
have anything eluted from the HPLC column (Figure 5.3 D) and again present at the bottom of the gel.
In this study we used the Western blotting technique, a widely used analytical tool in detection and 
identification of mucins (Dunn 1986) and HPLC Mono Q analysis to isolate mucins according to charge 
(Thornton et al, 1996). This is the first study in this laboratory to show the presence of MUC5AC, 
MUC5B and MUC2 in normal airways after HPLC Mono Q analysis and Western blot detection. In 
the TB study conducted in this laboratory by Ureshnie Govender in 2004-2006 (Govender 2006), crude 
sputum was used to detect mucin type by Western blotting and autoradiography. We had available to us 
a supersensitive ECL detection kit, which required autoradiography or chemi‑imaging for visualisation 
of the detected bands on the blot. Chemi-imaging was more sensitive and gave better visualisation than 
autoradiography. However, in the work of Govender (2006), MUC5AC and other mucins, up-regulated 
in disease were very easily detectable using autoradiography. MUC5AC sensitivity was low in the 
normal group of the previous study (Govender, 2006) and could not be detected in the crude sputa. It is 
suggested that for future TB studies, purified mucin should be used. In uninfected TB adults MUC5B 
and 2 glycoforms of MUC2 were detected (Govender 2006). However, in this study no glycoforms of 










In these experiments on normal airways sputum electrophoresis was done on 1% agarose gels. 
Agarose gels appear to optimally separate large charged and uncharged glycoproteins (Tytgat et al, 
1995). Exposure times on western blots for detection of respiratory mucins all varied as the method 
used depended on the concentration of the sample and the apparatus used to visualise the bands. A 
super‑sensitive ECL detection kit was used as the purified reduced mucin was in low amounts and 
ECL lumiglo detects nanogram amounts of sample.  The sensitivity to the ECL could be amplified by 
exposing the western blot to the reagents for longer than the allocated minute, or detection using either 
chemi‑imaging or X‑ray film for autoradiography and at different time periods. The nitrocellulose 
membranes were used repeatedly for different antibody detection by stripping the membrane with 
stripping buffer which saved time and money (a very important consideration in our laboratory). This 
buffer and/or the chemi-imager could have caused the distortion of the bands and bad background.
In summary, we have shown that the major respiratory mucins MUC5AC (in all the controls) and 
MUC5B (in only 50% of the controls) are present in those subjects who have no known diagnosed 
respiratory or lung condition, which in this study we regarded as normals (N). Interestingly, we showed 
some MUC2 was present in N9, a current smoker, N14 a volunteer that never smoked and N12 an ex-
smoker (living with an ex‑TB patient). The electrophoretic profile of these MUC2 positive subjects 
was very similar to that of the crude mucus electrophoretic profile of TB patients (Govender 2006). 
Subject N12 also showed MUC2 material eluting from the HPLC Mono Q column. The fact that he 
lives with an ex-TB sufferer is the likely explanation of why he had more MUC2 material in his sputa, 
enough for us to obtain a positive result for the HPLC analysis. It should be noted that the incidence 
of TB in South Africa is probably one of the highest in the world (Zar et al, 2000). Almost everyone 
is exposed to TB although not everyone suffers from it or is diagnosed with it. Sadly, there are also 
multi-drug resistant cases of TB increasingly being recorded in South Africa (Zager and McNerney 
2008). Due to the confidential nature of this study we are considering ways to get this information to 
the MUC2 positive cases in this study, to encourage them to be tested.
Finally, the steeper gradient of the HPLC eluted fractions of certain MUC5B eluted profiles is suggestive 
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Figure 5-1: Agarose gel electrophoresis (a representative group of gels) of reduced and alkylated 









Sputum induced with 3% NaCl from normal airways was solubilised in 6M GuHCl and then dialysed 
against 6M Urea. Mucins were reduced and alkylated and subjected to electrophoresis on a 1% agarose 
gel as descibed in the experimental section. 
(A) Is a normal sample (N3) with a concentration of 0.45mg/ml of purified mucin which has been 
exposed to ECL for 1 minute and detected by chemi-imaging after 1 minute. Lane 1, positive 
control, PMP; lane 2, crude sputum; lane 3, reduced purified mucin; lanes 4-11, HPLC fractions 
60-67 and lane 12, negative control, (sample application buffer SAB). 
(B) Is a normal sample (N4) with a concentration of 0.39mg/ml of purified mucin which has been 
exposed to ECL for 1 minute and detected by chemi-imaging after 3 minutes. Lane 1, positive 
control, PMP;  lane 2, crude sputum; lane 3, reduced purified mucin; lanes 4-11, HPLC fractions 
66-73 and lane 12, the negative control, (SAB).
(C) Is a normal sample (N7) with a concentration of 0.86mg/ml of purified mucin which has been 
exposed to ECL for 1 minute and detected by chemi-imaging after 30 seconds. Lane 1, positive 
control, PMP; lane 2, crude sputum; lane 3, reduced purified mucin; lanes 4-11, HPLC fractions 
74-82 and lane 12, negative control, (SAB). 
(D) Is a normal sample (N9) with a concentration of 0.38mg/ml of purified mucin which has been 
exposed to ECL for 1 minute and detected by chemi-imaging after 3 minutes. Lane 1, positive 
control, PMP; lane 2, crude sputum; lane 3, reduced purified mucin; lanes 4-11, HPLC fractions 
63-70 and lane 12, negative control,  (SAB). 
(E) Is a normal sample (N12) with a concentration of 0.18mg/ml of purified mucin which has been 
exposed to ECL for 1 minute and detected by chemi-imaging after 1 minute. Lane 1, positive 
control, PMP; lane 2, crude sputum; lane 3, reduced purified mucin; lanes 4-11, HPLC fractions 
74-81 and lane 12, negative control,  (SAB). 
(F) Is a normal sample (N14) with a concentration of 0.1mg/ml of purified mucin which has been 
exposed to ECL for 1 minute and detected by chemi-imaging after 1 minute. Lane 1, positive 
control, PMP; lane 2, crude sputum; lane 3, reduced purified mucin; lanes 4-11, HPLC fractions 
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Figure 5-2: Agarose gel electrophoresis (a representative group of gels) of reduced and alkylated 










Sputum induced with 3% NaCl from normal airways was solubilised in 6M GuHCl and then dialysed 
against 6M Urea. Mucins were reduced and alkylated and subjected to electrophoresis on a 1% 
agarose gel as descibed in experimental section.
(A) Is a normal sample (N7) with a concentration of 0.86mg/ml of purified mucin which has been 
exposed to ECL for 1 minute and detected by chemi-imaging after 3minutes. Lane 1, positive 
control, PMP; lane 2, crude sputum; lane 3, reduced purified mucin; lanes 4-11, HPLC fractions 
74-82 and lane 12, negative control, (SAB). 
(B) Is a normal sample (N12) with a concentration of 0.18mg/ml of purified mucin which has been 
exposed to ECL for 1 minute and detected by chemi-imaging after 10 minutes. Lane 1, positive 
control, PMP; lane 2, crude sputum; lane 3, reduced purified mucin; lanes 4-11, HPLC fractions 
74-81 and lane 12, negative control, (SAB). 
(C) Is a normal sample (N14) with a concentration of 0.1mg/ml of purified mucin which has been 
exposed to ECL for 1 minute and detected by chemi-imaging after 5 minutes. Lane 1, positive 
control, PMP; lane 2, crude sputum; lane 3, reduced purified mucin; lane 4-11, HPLC fractions 
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Figure 5-3: Agarose gel electrophoresis (a representative group of gels) of reduced and alkylated 










Sputum induced with 3% NaCl from normal airways was solubilised in 6M GuHCl and then dialysed 
against 6M Urea. Mucins were reduced and alkylated and subjected to electrophoresis on a 1% agarose 
gel as descibed in experimental section.
(A) Is a normal sample (N7) with a concentration of 0.86mg/ml of purified mucin which has been 
exposed to ECL for 1 minute and detected by  chemi-imaging after 3minutes. Lane 1, positive 
control, PMP; lane 2, crude sputum; lane 3, reduced purified mucin; lanes 4-11, HPLC fractions 
74-82 and lane 12, negative control, (SAB). 
(B) Is a normal sample (N9) with a concentration of 0.38mg/ml of purified mucin which has been 
exposed to ECL for 1 minute and detected by chemi-imaging after 5 minutes. Lane 1, positive 
control, PMP; lane 2, crude sputum; lane 3, reduced purified mucin; lanes 4-11, HPLC fractions 
63-70 and lane 12, negative control, (SAB). 
(C) Is a normal sample (N12) with a concentration of 0.18mg/ml of purified mucin which has been 
exposed to ECL for 1 minute and detected by chemi-imaging after 5 minutes. Lane 1, positive 
control, PMP; lane 2, crude sputum; lane 3, reduced purified mucin; lanes 4-11, HPLC fractions 
74-81 and lane 12, negative control, (SAB). 
(D) Is a normal sample (N14) with a concentration of 0.1mg/ml of purified mucin which has been 
exposed to ECL for 1 minute and detected by chemi-imaging after 10 minutes. Lane 1, positive 
control, PMP; lane 2, crude sputum; lane 3, reduced purified mucin; lanes 4-11, HPLC fractions 
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Figure 5.4: Agarose gel electrophoresis of TB sputa for detection of MUC2.
Lane 1: positive purified colon mucin; lane 2: saliva; lane 3, purified gastric mucin; lane  4‑6, volunteer 
sputa control; lane 7 and 8, TB positive adults; lane 9 and 10, TB positive children; lane 11, ‘possible’ 












Identification of respiratory mucins in airways of 
subjects with asthma (A) by Western Blotting
6.1 Identification of mucins by Western Blotting
This chapter describes the characterisation of mucins in sputa in airways of asthmatic patients by 
Western blotting. Crude sputa solubilised in 4M GuHCl and a cocktail of proteolytic inhibitors, 10mM 
EDTA and 1mM PMSF were collected from 15 asthma patients attending hospitals in the Cape Town 
region. The mucins were reduced with DTT and subsequently alkylated with IAA to obtain mucin 
subunits with epitopes exposed for Western blot detection (Kirkham et al, 2002). The reduced mucin 
subunits were loaded onto 1% agarose gels and electrophoresed to separate them on the basis of 
charge. Equal volumes (50µl) of mucin sample from individual patients were loaded onto the gel 
with the aim of detecting mucins of specific charge and possible glycoforms for each mucin type. 
Following electrophoresis the samples were vacuum-blotted onto a nitrocellulose membrane to 
confirm the presence of the major respiratory mucins, MUC5AC and MUC5B (Kirkham et al, 2002) 
and to investigate the possible presence of the minor MUC2 mucin component in asthmatic secretions. 
Western blots of purified, reduced asthma mucin samples were analysed with three polyclonal anti‑sera 
that recognise protein epitopes on the VNTR regions of MUC5AC, MUC5B and MUC2.
6.2 Results
MUC5AC, MUC5B and MUC2 are known mucin components of pseudomyxoma peritoneii (PMP) 
(O’Connell et al, 2002; Mall et al, 2007). PMP was used as a suitable positive control for the detection 
of the respiratory mucins being investigated. The specificity of MUC5AC antibody LUM 5‑1, in the 
blots of samples from asthma patients (Figure 6.1) was confirmed against the purified PMP (positive 
control, Figure 6.1 A-H, lanes 1) and sample application buffer (negative control, Figure 6.1 A-H, lanes 
12). Crude sputum was positive for MUC5AC and appeared as a broad smear-band (Figure 6.1 A-H, 
lanes 2), which penetrated the top of the gel due to the larger size of this unreduced material compared 
to the purified reduced mucin which easily entered the gels (Figure 6.1 A‑H, lanes 3). The membranes 
of the Western blot were first probed with MUC5AC, then stripped and probed with MUC5B antibody 
and again stripped and probed with MUC2 antibody (Henke et al, 2004; Govender 2006). This was 











mucin and this method saved sample, time and was cost effective.
MUC5AC was present in all the asthma secretions (15/15) analysed. The charge variation is clear and 
greater between the HPLC fractions eluted from the Mono Q column (Figure 6.1 A-G, lanes 4-11, H 
lanes 4-9) of the asthma group than the HPLC fractions eluted from the Mono Q column of the normal 
and the COPD groups (Chapter 5, Figure 5.1 and Chapter 7, Figure 7.1). There is some variation in 
the gradients of the MUC5AC samples from the asthma group, with some mucin samples showing 
a slightly steeper gradient (Figure 6.1 A, C, F and G) than others (Figure 6.1 B, D, E and H). The 
intensity of the MUC5AC smear-bands in the asthma group is similar to the MUC5AC smear-bands 
of the normal group (all data not shown). The specificity of the MUC5AC antibody was supported, 
not only by the positive control (Figure 6.1 A-H, lanes 1), but also by the absence of this mucin in the 
sample application buffer (negative control, Figure 6.1 A-H, lanes 12). The position and appearance 
of MUC5AC on the western blot of the asthma secretions (Figure 6.1) is similar to that described by 
Thornton et al, (1996), where MUC5AC was found as the major respiratory mucin in asthma secretions.
MUC5B was present in 14 of the 15 asthma samples (not all data shown) (Figure 6.2). Once again the 
specificity of the MUC5B antibody showed reactivity to the positive control (Figure 6.2 A‑D, lane 1, 
arrows) and no reactivity to the negative control (Figure 6.2 A-D, lanes 12). The intensity of the bands 
for MUC5B (Figure 6.2, arrows) by comparison, was weaker than MUC5AC (Figure 6.1). MUC5B in 
the asthma group (Figure 6.2) showed similar electrophoretic mobility profiles to that of MUC5B in 
the normal group (Chapter 5, Figure 5.2). 
MUC2 was present in 8 of the 15 asthma samples (not all data shown) (Figure 6.3). The location of 
the bands (Figure 6.3 A and B, lanes 2-11 and C, lanes 2-9) illustrated by the arrows, show that these 
mucins are low charge glycoforms of MUC2 unlike the high charge glycoforms seen in some of the 












Asthma is a respiratory disease that affects the lower respiratory tract (Dodge et al, 1986). There 
are two major respiratory mucins found in the airways of patients suffering from asthma, MUC5AC 
and MUC5B and some MUC2 (Davies et al, 1999). MUC5AC is produced from the goblet cells in 
the surface epithelial layer and MUC5B is produced from the submucosal glands. The production 
of mucus is essential in keeping the airways lubricated and clear of any pathogens. However,  the 
over-production of the respiratory mucus is a key characteristic of asthma causing mucus plugging in 
the airways that can lead to morbidity and mortality of these patients (Sheehan et al, 1995; Rose and 
Voynow 2006). The major respiratory mucins MUC5AC and MUC5B were found to be present in the 
asthma group in this study. Also MUC2, that responds to inflammation has also been shown (Vinall 
et al, 2000) in 8/15. The sputa collected from patients with asthma were, upon observation, more 
tenacious causing difficulty for the patients to expectorate easily. 
MUC5AC was present in 15 out of 15 asthma samples collected. There is more of a charge variation 
in the asthma group (Figure 6.1) when compared to the normal group (Chapter 5, Figure 5.1), but 
MUC5AC expression appeared to be homogenous in both groups. The crude unreduced, non‑purified 
mucus (Figure 6.1 A-H, lanes 2) appeared mostly on top of the gel because of its high molecular weight 
and presented with a broader smear‑band than the reduced purified mucin (Figure 6.1 A‑H, lanes 3).  
The presence of MUC5B was observed in 14 of the 15 asthma samples (not all data shown).  The 
reason for the absence of MUC5B in the one sample is unknown (not shown) as the clinical data 
for that patient is similar to those whose sputa had MUC5B.  The fractions eluted from the Mono Q 
column as indicated by the arrows showed a charge gradient between these eluted fractions (Figure 6.2, 
A, B, D, lanes 4-11 and C, lanes 4-9) indicating that the mucin population separated by HPLC Mono 
Q column is based on charge. The presence of MUC5B in secretions of asthmatic patients (14/15) was 
greater than the MUC5B in ‘healthy’ normal volunteers (5/10). This is possibly an indicator of inter-
individual variation within the asthma and the normal groups. 
MUC2 was present in 9 of the 15 asthma samples collected. MUC2 was not as highly charged as the 
MUC2 found in the normal (Chapter 5, Figure 5.3) and TB samples (Chapter 5, Figure 5.4). MUC2 











sputum of healthy normal volunteers (3/10). This suggests that MUC2 should be further analysed in 
a larger cohort of patients with asthma. The presence of MUC2 is an indicator of inflammation in the 
airways (Davies et al, 1999). The intensity of the bands for MUC2 (Figure 6.3, arrows) was not as 
great as the intensity of the bands for MUC5AC (Figure 6.1). The explanation for this could be due 
to the technique used, for example, stripping of the membranes for re‑probing for each respiratory 
mucin detected and the varying concentrations of the samples. The positioning of the bands is also of 
interest as they differ from the normal group (Chapter 5, Figure 5.3), indicating that the MUC2 in the 
asthma group (Figure 6.3) is less charged because it is higher up in the gel when compared to the highly 
charged MUC2, which is lower in the gel of sputa samples from the normal group that have MUC2. 
However, we have given a possible explanation of why some of the normal volunteers have MUC2.
The electrophoresis on asthma samples was done on 1% agarose gels, which optimally separates the 
large charged and uncharged mucins that have been analysed by HPLC (Tytgat et al, 1995). Visualisation 
of antibody reaction was done by chemi-imager and autoradiography. Both methods were used as they 
were easily accessible. The ECL super-sensitive kit was used for detection of the bands of all the 
asthma samples as the concentrations of these samples varied and small amounts could therefore be 
detected. The electrophoretic differences observed in all lanes of the blots are largely indicative of the 
intrinsic negative charges of the mucins, which were also observed by Kirkham et al (2002, 2008). The 
mucins differed in terms of electrophoretic mobility, which was attributed to differences in their charge 
densities (Thornton et al, 1995). In this study no glycoforms of MUC5AC and MUC5B were present 
in the asthma group, which is similar to what was observed in the normal group. 
The literature shows that MUC5AC is the dominant mucin in asthma airways (Hovenberg et al, 1996; 
Ordonez et al, 2001; Kirkham et al, 2002). Methodological differences could probably explain the 
differences in results obtained from this study when compared to that in the literature (Kirkham et al, 
2008). The results presented here show that the electrophoretic profile of the MUC5AC is similar to 
the MUC5B in the asthmatic airways, which differs from what was previously reported in the literature 
(Kirkham et al, 2002; Govender 2006). We do, however, show that MUC5AC and MUC5B are the 
predominant species in mucus from the asthma airways. Comparative analyses of mucin levels are more 
challenging than simply identifying specific mucins because of the inherent difficulties in solubilising 











In summary, mucins produced from the asthma group presented with the respiratory mucins under 
investigation namely, MUC5AC, MUC5B and MUC2. The airways response to mucus hypersecretion 
was observed by the presence of both MUC5AC and MUC5B in nearly all the asthma samples. MUC5B 
presented in more asthma samples (14/15) compared to the normal group (5/10) and the COPD group 
(11/15), which could be significant. However, a larger study would be required to determine this. This 
could possibly be one of the reasons why the mucus of asthmatic patients is so viscous. MUC2 which 
was present in 8 out the 15 asthma samples, is an indicator of inflammation and disease in the airways 
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Figure 6-1: Agarose-gel electrophoresis (a representative group) of reduced and alkylated mucins 










A 1% (w/v) agarose gel with aliquots of selected fractions was electrophoresed for 3h at 65V and 
400mA in 1xTAE to separate mucins based on charge after anion-exchange analysis and subsequently 
blotted onto nitrocellulose as described in experimental section. Bands were visualised using ECL 
western detection kit after different exposure times using a chemi-imager and autoradiography. 
(A) An asthma sample (A38), with a concentration of 0.93mg/ml of purified mucin. Lane 1, positive 
control; lane 2, crude sputum; lane 3, purified reduced mucin; lane 4-11, HPLC fractions 78-84 
and lane 12, negative control. Bands were visualised after 2 minutes with a chemi-imager.
(B) An asthma sample (A41), with a concentration of 3.95mg/ml of purified mucin. Lane 1, positive 
control; lane 2, crude sputum; lane 3, purified reduced mucin; lanes 4-11, HPLC fractions 59-66 
and lane 12, negative control. Bands were visualised by chemi-imaging after 2 minutes.
(C) An asthma sample (A42), with a concentration of 0.72mg/ml of purified mucin. Lane 1, positive 
control; lane 2, crude sputum; lane 3, purified reduced mucin; lanes 4-11, HPLC fractions 75-82 
and lane 12, negative control. Bands were visualised by chemi-imaging after 2 minutes.
(D) An asthma sample (A43), with a concentration of 0.88mg/ml of purified mucin. Lane 1, positive 
control; lane 2, crude sputum; lane 3, purified reduced mucin; lanes 4-11, HPLC fractions 76-84 
and lane 12, negative control. Bands were visualised by chemi-imaging after 45 seconds.
(E) An asthma sample (A44), with a concentration of 0.53mg/ml of purified mucin. Lane 1, positive 
control; lane 2, crude sputum; lane 3, purified reduced mucin; lanes 4-11, HPLC fractions 110-117 
and lane 12, negative control. Bands were visualised by chemi-imaging after 2 minutes.
(F) An asthma sample (A45), with a concentration of 12.33mg/ml of purified mucin. Lane 1, positive 
control; lane 2, crude sputum; lane 3, purified reduced mucin; lanes 4-11, HPLC fractions 85-94 
and lane 12, negative control. Bands were visualised by X-ray film using autoradiography after 2 
minutes.
(G) An asthma sample (A46), with a concentration of 0.78mg/ml of purified mucin. Lane 1, positive 
control; lane 2, crude sputum; lane 3, purified reduced mucin; lanes 4-11, HPLC fractions 74-83 
and lane 12, negative control. Bands were visualised by chemi-imaging after 1 minute.
(H) An asthma sample (A47), with a concentration of 0.53mg/ml of purified mucin. Lane 1, positive 
control; lane 2, crude sputum; lane 3, purified reduced mucin; lanes 4-9, HPLC fractions 76-81 
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Figure 6-2:  Agarose-gel electrophoresis (a representative group) of reduced and alkylated mucins 










A 1% (w/v) agarose gel with aliquots of selected fractions was electrophoresed for 3h at 65V and 
400mA in 1xTAE to separate mucins based on charge after anion-exchange analysis and subsequently 
blotted onto nitrocellulose as described in experimental section. Bands were visualised using ECL 
Western detection kit after different exposure times using chemi-imager.
(A)  An asthma sample (A44), with a concentration of 0.53mg/ml of purified mucin. Lane 1, positive 
control; lane 2, crude sputum; lane 3, purified reduced mucin; lanes 4-11, HPLC fractions 110-117 
and lane 12, negative control. Bands were visualised by chemi-imaging after 1 minute.
(B)  An asthma sample (A46), with a concentration of 0.78mg/ml of purified mucin. Lane 1, positive 
control; lane 2, crude sputum; lane 3, purified reduced mucin; lanes 4-11, HPLC fractions 74-83 
and lane 12, negative control. Bands were visualised by chemi-imaging after 1 minute.
(C)  An asthma sample (A47), with a concentration of 0.53mg/ml of purified mucin. Lane 1, positive 
control; lane 2, crude sputum; lane 3, purified reduced mucin; lanes 4-9, HPLC fractions 76-81 and 
lane 12, negative control. Bands were visualised by chemi-imaging after 1 minute.
(D)  An asthma sample (A52), with a concentration of 0.49mg/ml of purified mucin. Lane 1, positive 
control; lane 2, crude sputum; lane 3, purified reduced mucin; lanes 4-11, HPLC fractions 76-81 
and lane 12, negative control. Bands were visualised by chemi-imaging after 1 minute.
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Figure 6-3: Agarose-gel electrophoresis (a representative group) of reduced and alkylated mucins 










A 1% (w/v) agarose gel with aliquots of selected fractions was electrophoresed for 3h at 65V and 
400mA in 1xTAE to separate mucins based on charge after anion-exchange analysis and subsequently 
blotted onto nitrocellulose as described in experimental section. Bands were visualised using ECL 
Western detection kit after different exposure times using chemi-imager.
(A) An asthma sample (A43), with a concentration of 0.88mg/ml of purified mucin. Lane 1, positive 
control; lane 2, crude sputum; lane 3, purified reduced mucin; lanes 4-11, HPLC fractions 76-84 
and lane 12, negative control. Bands were visualised by chemi-imaging after 1 minute.
(B) An asthma sample (A52), with a concentration of 0.49mg/ml of purified mucin. Lane 1, positive 
control; lane 2, crude sputum; lane 3, purified reduced mucin; lanes 4-11, HPLC fractions 76-81 
and lane 12, negative control. Bands were visualised by chemi-imaging after 1 minute.
(C) An asthma sample (A47), with a concentration of 0.53mg/ml of purified mucin. Lane 1, positive 
control; lane 2, crude sputum; lane 3, purified reduced mucin; lanes 4-9, HPLC fractions 76-81 












Identification of respiratory mucins in airways of 
subjects with COPD (C) by Western Blotting
7.1 Identification of mucins by Western Blotting
The objective of this chapter was to characterise mucins in sputa in airways from COPD patients by 
Western blotting. Crude sputa from 15 patients suffering from COPD and attending hospitals in the Cape 
Town region were solubilised in 4M GuHCl and proteolytic inhibitors. Equal volumes of sputa samples 
from a group of COPD patients were loaded onto a 1% agarose gel with the aim of detecting mucins of 
specific charge and the possible glycoforms present for each mucin type. Following electrophoresis the 
samples were vacuum blotted onto a nitrocellulose membrane to confirm the presence of the dominant 
respiratory mucins MUC5AC and MUC5B and the minor MUC2 component of respiratory mucus 
(Kirkham et al, 2002). 
7.2 Results
Using mucin specific anti‑sera, MUC5AC was observed in all 15 COPD sputa samples (Figure 7.1). 
MUC5B was present in 11/15 (Figure 7.2) and MUC2 was present in 7/15 (Figure 7.3) of the COPD 
sputa samples (not all data shown). In the airways of patients suffering from COPD, proteases from 
neutrophils, the predominant inflammatory cells, cleave off mucins produced in goblet cells of the 
surface epithelium (Groneberg and Chung 2004; Rogers 2004). Patients with COPD produced more 
sputum and thus expectoration of the sample was easier. 
Western blotting was performed to identify the presence of mucins in sputa samples of patients with 
COPD. Mucin samples were loaded on a 1% agarose gel and subjected to electrophoresis. Mucins were 
then transferred from the gel to a nitrocellulose membrane and probed with rabbit anti-MUC5AC, rabbit 
anti‑MUC5B and rabbit anti‑MUC2 polyclonal antibodies (Chapter 2). Western blotting confirmed the 
presence of MUC5AC (Figure 7.1), MUC5B (Figure 7.2) and MUC2 (Figure 7.3) in COPD sputa 
samples. MUC5AC was present in all the sputa samples (15/15) analysed in this study, MUC5B in 
11/15 while MUC2 was present in fewer (7/15). 











PMP was a suitable control for mucins found in COPD patients as it is positive for MUC5AC, MUC5B 
and MUC2 (O’Connell et al, 2002; O’Connell et al, 2002; Mall et al, 2007). Sample application buffer 
was used as a negative control in all the blots for this study (Figure 7.1, 7.2 and 7.3 lanes 12).
MUC5AC was positive in the crude sputa in the blots (Figure 7.1 A-F, lanes 2) and appeared as a large 
smear-band of material from the top of the gel penetrating quite far into the gel. There was no distinct 
band for the crude sputa, only a large smear. The purified reduced mucin of the same sputa sample 
(Figure 7.1 A-F, lanes 3) gave a more distinct band for MUC5AC and electrophoresed in a position 
similar to those fractions eluted from the Mono Q column (Figure 7.1 A-E, lanes 4-11 and F, lanes 4-7, 
arrows). The fractions eluted from the Mono Q column electrophoresed with a slightly steeper gradient 
(Figure 7.1 B, C and D, lanes 4-11) than the others (Figure 7.1 A and E, lanes 4-11 and F, lanes 4-7, 
arrows).  
The presence of MUC5B (Figure 7.2) in the COPD secretions was less when compared to MUC5AC 
(Figure 7.1) (not all data shown). MUC5B was present in the positive control in all the blots (Figure 
7.2, A-D, lanes 1). The crude unreduced sputa presented as a smear (Figure 7.2 A, B and D lanes 2) and 
as a single band slightly entering the gel (Figure 7.2 C, lane 2, arrow). The presence of MUC5B in the 
purified reduced mucin was observed (Figure 7.2 A‑C, lanes 3) as a single band in the gel. Interestingly, 
MUC5B was observed as two bands indicating the presence of two glycoforms of MUC5B in COPD 
(Figure 7.2 D, lane 3).  This however was only observed in 1 out of the 15 COPD samples. The 
purified reduced mucins (lanes 3) electrophoresed slightly different to the reduced samples eluted from 
the Mono Q column. The fractions eluted from the Mono Q column showed a slight charge gradient 
(Figure 7.2 A and B, lanes 4-11 and D, lanes 4-7, arrows) and a more distinct gradient was observed 
(Figure 7.2 C, lanes 4-11, arrows). Sample application buffer was used as a negative control (Figure 
7.2 A-D, lanes 12).   
Trace amounts of MUC2 were present in 7 of the 15 COPD sputa samples (Figure 7.3) compared to 
both MUC5AC (15/15) and MUC5B (11/15) (not all data shown). The positive control (Figure 7.3 
A-C, lanes 1, arrows) gave two bands for MUC2. This is interesting as PMP always presented as a 
single band (Mall et al, 2007). This could be due to some protein contamination of the laboratory 











(Figure 7.3 A‑C lanes 2, arrows). The purified reduced samples are illustrated as single defined bands 
on the blot (Figure 7.3 A-C, lanes 3, arrows). There are slight bands showing the presence of MUC2 in 
the fractions eluted from the Mono Q column during HPLC analysis (Figure 7.3 A, lanes 4-11, arrows). 
The MUC2 bands were very weak but visible in the blot (Figure 7.3 B, lanes 4-11 and C, lanes 4-7, 
arrows). The negative control used in this study was sample application buffer (Figure 7.3 A-C, lanes 
12).
7.3 Discussion
Chronic obstructive pulmonary disease (COPD) is a respiratory disease that affects the lower airways 
and is comprised of pulmonary emphysema, chronic bronchitis and chronic bronchiolitis (Rogers 2000; 
Yoshida and Tuder 2007). COPD patients invariably produce more sputum than patients suffering from 
any other respiratory disease (Aikawa et al, 1989; Rogers 2000). This fact is reflected in this study 
(see Chapter 3), where the most sputa was produced from the COPD patients. Western blotting was 
conducted to determine the identity of the respiratory mucins found in the COPD sputa. This analytical 
tool is widely used in the detection of mucins (Dunn 1986). Agarose gel electrophoresis with a slightly 
modified method of Thornton et al, (1996) was the method of choice in the separation of mucins after 
HPLC analysis using the Mono Q column in this study. Agarose gels appear to optimally separate large 
charge and uncharged glycoproteins.  
Suitable positive and negative controls were used in this study. Material from a patient suffering from 
pseudomyxoma peritoneii (PMP) was used throughout this study (see Chapter 5 and Chapter 6) as a 
positive control as it has high reactivity with the respiratory mucins of interest namely, MUC5AC, 
MUC5B and MUC2 (Mall et al, 2007). Interestingly, this positive control showed two bands when 
probed with MUC2 which previously presented as a smear regardless of the anti-sera that was being 
analysed (Mall et al, 2007). It is possible that some protein material has been detected here (Mall et al, 
2007). Sample application buffer was consistently used throughout this study, as the negative control. 
There was no distinct crude sputa band present as the unreduced non‑purified mucus in its intact form 
could not enter the gel easily due to its large size in all the blots. The purified reduced mucins were 
separated by agarose gel electrophoresis and subsequently detected by Western blotting with anti‑sera 
to the respiratory tract mucins. Electrophoresis is expected to separate lower molecular mass proteins 











The MUC5AC fractions eluted from the Mono Q column (Figure 7.1) are consistent with the literature 
in the positioning of the bands and with a slight charge gradient (Figure 7.1 A, B, E and F) and in some 
cases there was a more distinct gradient (Figure 7.1 C, D). There was also homogeneity of the bands 
showing that these fractions all belong to the same species of MUC5AC mucin (Kirkham et al, 2002). 
The fractions eluted from the Mono Q column for MUC5B (Figure 7.2) had a slightly greater charge 
gradient than MUC5AC (Figure 7.1). 
MUC5B was present in 11 out of the 15 COPD samples collected and was observed as faint (Figure 
7.2 A, B and D) but detectable bands (Figure 7.2 C). The charge separation of MUC5B between the 
fractions eluted in lanes 4-11 from the Mono Q column (Figure 7.2 C, arrows) was more distinct than 
that of the other MUC5B samples represented (Figure 7.2 A, B and D). Interestingly, one sample 
showed the presence of 2 bands indicating the presence of MUC5B glycoforms in the purified reduced 
sample, before the mucin was eluted from the Mono Q column as seen in lane 3 (Figure 7.2 D). 
Glycoforms of MUC5B present in the mucus of the respiratory tract of a patient who died of status 
asthmaticus has been reported previously (Thornton et al, 1997).
There were low levels of expression in all the mucin samples that were positive for MUC2 (Figure 
7.3 A‑C) (not all data shown). MUC2 was present in the crude sputa, purified reduced mucin and the 
fractions eluted from the Mono Q column (Figure 7.3 A-C). There was a slight charge gradient visible.
MUC5AC mucin in this study is consistent with the literature which describes it as a homogenous 
species compared to the heterogenous MUC5B mucin (Kirkham et al, 2002). Mucus hypersecretion 
is a contributory factor in the progression of COPD (Rogers 2000; Kirkham et al, 2008). This study 
shows that airway mucus is not a single substance but is comprised of variable amounts of MUC5AC, 
MUC5B and MUC2 glycoproteins (Thornton and Sheehan 2004). The results obtained from this study 
showed no overall significant change in the type of mucin found in the respiratory tract of COPD 
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Figure 7-1: Agarose gel electrophoresis (a representative group of gels) of reduced and alkylated 









A 1% (w/v) agarose gel with aliquots of selected fractions was electrophoresed for 3h at 65V and 
400mA in 1xTAE to separate mucins based on charge after anion-exchange analysis and subsequently 
blotted onto nitrocellulose as described in Experimental section. Bands were visualised using ECL 
Western detection kit after different exposure times using an autoradiograph machine and by chemi-
imaging.
(A)  A COPD sample (C31), with a concentration of 0.69mg/ml of purified mucin. Lane 1, positive 
control, PMP; lane 2, crude sputum; lane 3, purified reduced mucin; lanes 4-11, HPLC fractions 
76-83 and lane 12, negative control, SAB; after 1 minute exposure to X-ray film and detected using 
autoradiography.
(B)  A COPD sample (C51), with a concentration of 6.5mg/ml of purified mucin. Lane 1, positive 
control, PMP; lane 2, crude sputum; lane 3, purified reduced mucin; lanes 4-11, HPLC fractions 
61-68 and lane 12, negative control, SAB; after 1 minute exposure to X-ray film and detected using 
autoradiography.
(C)  A COPD sample (C58), with a concentration of 3.9mg/ml of purified mucin. Lane 1, positive 
control, PMP; lane 2, crude sputum; lane 3, purified reduced mucin; lanes 4-11, HPLC fractions 
74-81 and lane 12, negative control, SAB; 30 seconds exposure to a chemi-imager.
(D)  A COPD sample (C61), with a concentration of 0.21mg/ml of purified mucin. Lane 1, positive 
control, PMP; lane 2, crude sputum; lane 3, purified reduced mucin; lanes 4-11, HPLC fractions 
75-82 and lane 12, negative control, SAB; after 1 minute exposure to a chemi-imager.
(E)  A COPD sample (C62), with a concentration of 0.78mg/ml of purified mucin. Lane 1, positive 
control, PMP; lane 2, crude sputum; lane 3, purified reduced mucin; lanes 4-11, HPLC fractions 
74-81 and lane 12, negative control, SAB; after 10 seconds exposure to a chemi-imager. 
(F)  A COPD sample (C55), with a concentration of 6.6mg/ml of purified mucin. Lane 1, positive 
control, PMP; lane 2, crude sputum; lane 3, purified reduced mucin; lanes 4-7, HPLC fractions 73-
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Figure 7-2: Agarose gel electrophoresis (a representative group of gels) of reduced and alkylated 










A 1% (w/v) agarose gel with aliquots of selected fractions was electrophoresed for 3h at 65V and 
400mA in 1xTAE to separate mucins based on charge after anion-exchange analysis and subsequently 
blotted onto nitrocellulose as described in Experimental section. Bands were visualised using ECL 
Western detection kit after different exposure times using an autoradiograph machine and by chemi-
imaging.
(A)  A COPD sample (C31), with a concentration of 0.69mg/ml of purified mucin. Lane 1, positive 
control, PMP; lane 2, crude sputum; lane 3, purified reduced mucin; lanes 4-11, HPLC fractions 
76-83 and lane 12, negative control, SAB; after 1 minute exposure to X-ray film and detected using 
autoradiography.
(B) A COPD sample (C58), with a concentration of 3.9mg/ml of purified mucin. Lane 1, positive con-
trol, PMP; lane 2, crude sputum; lane 3, purified reduced mucin; lanes 4-11, HPLC fractions 74-81 
and lane 12, negative control, SAB; after 1 minute exposure to a chemi-imager.
(C) A COPD sample (C62), with a concentration of 0.78mg/ml of purified mucin. Lane 1, positive con-
trol, PMP; lane 2, crude sputum; lane 3, purified reduced mucin; lanes 4-11, HPLC fractions 74-81 
and lane 12, negative control, SAB; after 10 seconds exposure to a chemi-imager.
(D) A COPD sample (C55), with a concentration of 6.6mg/ml of purified mucin. Lane 1, positive con-
trol, PMP; lane 2, crude sputum; lane 3, purified reduced mucin; lanes 4-7, HPLC fractions 73-76 
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Figure 7-3: Agarose gel electrophoresis (a representative group of gels) of reduced and alkylated 










A 1% (w/v) agarose gel with aliquots of selected fractions was electrophoresed for 3h at 65V and 400mA 
in 1xTAE to separate mucins based on charge after anion-exchange analysis and subsequently blotted 
onto nitrocellulose as described in Experimental section. Bands were visualised using ECL Western 
detection kit after different exposure times using an autoradiograph machine and chemi-imager.
(A) A COPD sample (C31), with a concentration of 0.69mg/ml of purified mucin. Lane 1, positive 
control, PMP; lane 2, crude sputum; lane 3, purified reduced mucin; lanes 4-11, HPLC fractions 
76-83 and lane 12, negative control, SAB; after 1 minute exposure to X-ray film and detected 
using autoradiography.
(B) A COPD sample (C58), with a concentration of 3.9mg/ml of purified mucin. Lane 1, positive 
control, PMP; lane 2, crude sputum; lane 3, purified reduced mucin; lanes 4-11, HPLC fractions 
74-81 and lane 12, negative control, SAB; after 1 minute exposure to a chemi-imager.
(C) A COPD sample (C55), with a concentration of 6.6mg/ml of purified mucin. Lane 1, positive 
control, PMP; lane 2, crude sputum; lane 3, purified reduced mucin; lanes 4-7, HPLC fractions 














The amino acid composition of the apomucins of the normal, asthma and COPD groups was determined 
by HPLC analysis of the purified reduced mucins of each group. One sample of each group was analysed 
for its amino acid composition by hydrolysing these samples to remove the carbohydrate chains from 
the mucin peptide and then placed on a HPLC column to elute the primary amino acids. Amino acid 
analysis was done to determine the composition of the respiratory apomucins from the normal, asthma 
and COPD groups under investigation during this study. 
8.2  Results
Serine and threonine combined appeared at 23.32 mol % in the normal group, at 21.16 mol % in the 
asthma group and at 23.55 mol % in the COPD group. The serine and threonine levels in the normal 
and COPD groups (23.38 mol % and 23.55 mol % respectively) compared closely to each other and 
combined showed to be slightly higher than the asthma group (21.16 mol %).
Serine, threonine and proline (PTS) combined appeared at 35.61 mol % in the normal group, at 36.33 
mol % in the asthma group and at 34.42 mol % in the COPD group. The PTS mol % was approximately 
similar for each group and there was only a 1 mol % difference between each group.
Glycine, threonine, serine, proline and alanine constituted 52.87 mol % of the normal group, 54.68 mol 




























Asp 7.08 6.80 7.46 7.30 7.01 7.2
Thr 13.04 12.8 11.88 11.8 14.11 14.2
Ser 10.28 10.00 9.28 9.20 9.44 9.60
Glu 10.64 10.30 13.10 13.00 11.85 12.00
Pro 12.29 12.29 15.17 15.17 10.87 11.20
Gly 9.81 9.50 11.60 11.50 10.55 10.70
Ala 7.45 7.20 6.75 6.60 6.95 7.10
Val 4.94 4.60 4.83 4.70 4.36 4.50
Met 1.19 0.90 1.07 0.90 0.59 0.80
Ile 2.84 2.50 2.28 2.10 2.35 2.50
Leu 6.21 5.90 5.66 5.50 5.26 5.40
Tyr 2.34 2.10 1.85 1.70 1.43 1.60
Phe 2.67 2.30 2.56 2.40 1.92 2.10
His 20.76 20.50 14.89 14.8 18.21 18.30
Lys 3.70 3.40 3.69 3.60 2.37 2.50
Arg 5.89 5.60 6.52 6.40 3.81 4.00
8.3  Discussion
As shown in the Table 8.1 the mucins found in all 3 groups contained a higher amount of threonine, 
serine, proline, glutamic acid, glycine and histidine in the peptide portion of the respiratory mucin. 
These results are similar to the findings of Woodward et al, (1982) which states that (threonine, serine, 
proline, glycine and alanine) account for 51 mol % of the amino acid residues in the respiratory mucus 
and are characteristic of the typical mucin composition. Amino acid analysis reveals high levels of 
serine, threonine and proline levels which is consistent with a mucin-like macromolecule. This amino 













Airways mucus hypersecretion is the main feature in respiratory diseases that leads to mortality and 
morbidity (Kim 2003; Rogers 2004; Rose and Voynow 2006). The lung uses specialised secretions 
produced by the airways to provide a renewable and transportable protective layer to interact with, 
neutralise, and remove inhaled toxic materials trapped in mucus (Samet and Cheng 1994). The major 
limitation of this study was the variation in the concentration of each sample collected from each 
group. To overcome this limitation, qualitative analyses of these mucins, after purification, were done 
by dissolving the freeze‑dried sample in 10 ml with 6M urea. Aliquots of 50µl of each fraction eluted 
from the HPLC Mono Q column were further analysed for identification of the mucins present in 
the samples in this study. This approach has previously been successful as reported by the group of 
Thornton et al (1997) in Manchester, United Kingdom.
The two respiratory diseases of interest investigated in this study were asthma and COPD, two of the 
leading causes of death due to respiratory arrest, in South Africa. This study was concerned with the 
isolation, purification and biochemical characterisation of mucus and mucins found in the respiratory 
tract of patients suffering from chronic airway diseases namely, asthma and COPD and then the 
comparison of these mucins to the ones found in the airways of normal healthy volunteers. This study 
is largely a qualitative one. The idea arose from an earlier finding that the mucus found in people 
suffering from asthma was more tenacious than in other respiratory diseases. 
The methods used in this study were caesium chloride density gradient ultracentrifugation in order to 
isolate and purify the mucins obtained from the three groups (normal, asthma and COPD). Once the 
mucins were purified, they were reduced with DTT and alkylated with IAA in order to keep the mucin 
its subunit form and therefore making it easier to analyse. The mucin subunit is smaller and therefore 
moves more easily through the gels and columns. The mucins were then separated according to charge 
using a HPLC Mono Q 5/50GL column to determine if there was any charge differences found in 
these respiratory mucins. The mucins, once separated by ion-exchange chromatography, were further 
analysed for mucin identification using agarose gels and western blot analysis. HPLC Mono Q column 











We now plan to widen our studies and include samples from other lung diseases such as TB and lung 
cancer.
The mucins investigated were MUC5AC and MUC5B, the two major respiratory mucins. MUC2 was 
also investigated, as it has also been found in the respiratory tract of diseased patients (Davies et al, 
1996). Mucin from a patient with pseudomyxoma peritoneii (PMP) was used as a positive control as 
it was found, in our laboratory, to have all the mucins of interest, namely, MUC5AC, MUC5B and 
MUC2 (Mall et al, 2007).
Purified PMP mucin was used as an effective positive control and used consistently throughout this 
study at a concentration of 1mg/ml and a loading of 50µl, which is approximately 50µg, as it was 
positive for all the respiratory mucins under investigation, namely, MUC5AC, MUC5B and MUC2. 
The same positive control was used throughout this study to keep consistency and to serve as a standard 
and also because the membranes were stripped with stripping buffer after each antibody detection to 
save sample, time and costs (Govender 2006). We could not load a standard concentration of sample, 
like the Thornton laboratory did, as the concentration of each sample we loaded onto each gel depended 
on the amount of mucin purified from each sputum sample collected. The reason the concentrations 
were not consistent was that there were difficulties faced when collecting sputa samples, for example, 
some of the patients were too tired to cough and when they coughed they produced more saliva than 
sputa. We did however, have some consistency by loading 50µl of 1mg/ml positive (PMP) control and 
50µl of each sample. This allowed us to have equivalent volumes of material loaded on the gel for all 
groups. Henke (2004) conducted a study on cystic fibrosis secretions where samples were loaded onto 
gels at either, the same concentration, or volume and the intensity of the detected bands for MUC5AC 
and MUC5B were similar in appearance. This suggests that the intensity of the mucin smear-bands is 
not directly related to the concentration of the sample loaded onto the gel. The intensity of the bands 
in this study is related to the positive control (PMP) used throughout the study, which was loaded at a 
standard concentration of 1mg/ml. It is hypothesized that a darker smear-band could be indicative of a 
greater number of epitopes on a single mucin (Henke et al, 2004).
The amino acid analysis revealed high levels of serine, threonine and proline namely, 35.61 mol % 











mucin-like macromolecule. The amino acid analysis presented with a high combined value of glycine, 
threonine, serine, proline and alanine in all 3 groups namely, 52.87 mol % in normal, 54.68 mol % in 
asthma and 51.92 in COPD group, which is indicative of a typical mucin amino acid profile. The amino 
acid profile of the mucin in all 3 groups is similar to results shown by Habte et al, 2007 and Govender, 
(2006) where approximately 51% of the amino acids comprise a typical mucin (Woodward et al, 1982). 
The individual serine, threonine and proline values did not dominate the amino acid composition and 
interestingly there were high levels of histidine. These samples were collected during spring (high 
allergy season), which could be a explanation for the high histidine levels.
MUC5AC was shown in all sputa samples collected, it was present in 5 females and 5 males in the 
normal group, 7 females and 8 males in those suffering from asthma and 4 females and 11 males in 
those suffering from COPD. MUC5AC has been reported as one of the major respiratory mucins in 
respiratory diseases such as asthma and COPD and has also been shown to be present in the airways 
of normal healthy volunteers (Rose and Voynow 2006; Thornton et al, 2007). MUC5AC presented as a 
single species in this and previous studies, with a more homogeneous charge distribution than the other 
respiratory mucins. The intensity of the MUC5AC bands in this study was similar to that of the positive 
(PMP) control. The intensity and the presence of the MUC5AC bands in the 3 groups were greater 
than the intensity and presence of the bands for MUC5B and MUC2. This could be that MUC5AC is 
produced from the lungs first as a defence mechanism or that the patient/volunteer did not cough up 
enough mucus to produce all 3 mucins at equal intensity (Thornton et al, 2007).
MUC5B was shown in 2 females and 3 males in the normal group, 6 females and 8 males in the asthma 
group and 3 females and 8 males in the COPD group. The low charge glycoform of MUC5B that 
was present in one sample (C55) in this study was similar to that of Thornton (Thornton et al, 1997; 
Thornton et al, 2000). The positioning of the bands on the gel was the same in these studies. We found 
the presence of glycoforms without trypsin digestion. It is suggested for future studies that trypsin 
digestion be used on these reduced purified mucins as it aids in better separation (Thornton et al, 1997; 
Davies et al, 1999).
MUC2 was only shown in 3 males in the normal group, 3 females and 5 males in the asthma group 











very controversial as the normal healthy respiratory tract has small amounts of MUC5AC and MUC5B 
and no trace of MUC2 (Thornton et al, 1994). The presence of MUC2 in the airways of normal healthy 
volunteers, could be due to other influences and irritations to the airways, for example environmental 
factors. The climate in South Africa and especially in Cape Town could play a serious role in causing 
distress or irritation to airways of healthy individuals because of the infamous wind “Black South 
Easter”. 
The presence of MUC5AC mucin was investigated using an antiserum raised against a synthetic 
peptide based on the sequence of the MUC5AC apoprotein (Hovenberg et al, 1996). MUC5AC is the 
predominant mucin in all three groups as it is observed in 100% of all the samples investigated during 
this study. MUC5B was present in most cases, which confirms that it is another major mucin. More 
MUC5B was seen in asthma and this could be the reason the mucus is so tenacious. MUC2, when 
compared to MUC5B and MUC5AC, is a minor mucin as it was present in only a few samples.
This study shows that mucus does not consist of a single substance but is comprised of variable 
amounts of MUC5AC, MUC5B and to a certain extent MUC2 glycoproteins. There were no significant 
differences found between the two diseases regarding the presence or absence of the major respiratory 
mucin MUC5AC, but there was a difference in the presence or absence of the other respiratory 
mucin MUC5B and to a small extent MUC2. Another approach to determine if there are differences 
between these groups would be to load known concentrations of sample and to compare the intensity 
of the bands produced on the gels. The intensity is measured by reflective densitometry, which is not 
available in this laboratory. It has been suggested by Thornton and Sheehan that MUC5AC is involved 
in mucociliary clearance of mucus (Thornton and Sheehan 2004). 
This thesis will contribute to the field of respiratory medicine as the presence of MUC2 could be 
used as a marker for the presence of disease whether it is an allergy or a respiratory disease. People 
who have MUC2 present in their airways should be tested by their physician for any complicating 
or associating factors. We have also shown that there are no major differences between the 3 groups, 
but that there are inter-individual variations within these 3 groups, for example, N14, which has the 
presence of MUC2 could mean that this volunteer is susceptible to allergies and asthma (according to 











Future work on this study could be to analyse a bigger cohort of sputum samples from each group. 
Follow up examinations of the normal volunteers that have MUC2 glycoforms associated with TB, if 
tested positive could confirm that the MUC2 in normal airways is a marker for respiratory disease. The 
high number of paitents’ with MUC5B in asthma could explain why the mucus is so tenacous in these 
patients.
We have now established a technique to use for the future, the first Mono Q HPLC in this region for 













A. Consent Information Form
UNIVERSITY OF CAPE TOWN 
 







We are doing a study on the mucus produced in your lungs. We wish to find out what 
exactly the mucus is made of and whether it is different in asthma and COPD and 
normals.  
 
You will be expected to undergo sputum induction which is the removal of mucus by 
breathing in aerosol saline; this procedure is harmless. We will place the mucus in a 




1. We will need to take your folder number (NOT YOUR NAME) from which 
we will get details of your age, gender and origin. All this information will be 
kept absolutely confidential and we promise not to use your sample for any 
other purpose than that which we have described.  
2. You have a right to say that you do not wish to take part in this study and be 
assured that it will not affect the treatment you receive in hospital.  
3. If you agree to participate in this research project now and then decide at a 
later time that you do not wish to continue, that is also fine. That decision will 
once again not affect your right to treatment and care. We will NOT test for 
HIV/AIDS. 
4. It is possible that we will publish the findings of this study but your name will 
not be mentioned.  
 
If there are any queries, please refer them to your clinician. If you think of any queries 
at a later date, please don’t hesitate to contact me at the telephone number below. 
 




Patient information and consent:  
 
I, _______________ give permission that my sputum obtained by sputum induction 




Folder Number DOB Gender Disease Medication 
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Guanidinium hydrochloride (287g) 
10mM EDTA (1.86g)
1mM PMSF (0.087g) (dissolve in few drops of ethanol) 
1M Tris-HCl pH 8.0
Put on heating block to dissolve at 37°C
 Make up to 500ml, put on heating block to dissolve at 37°C
Periodic Acid Solution
For 50 tubes





In Schiff’s reagent (6ml)




2 % anhydrous Na2CO3 (2g) 
 Made up in 0.1M NaOH (100ml)
 Solution B
1% CuSO4 (0.25g CuSO4 in 25ml dH2O)
2% Sodium tartrate (0.5g sodium tartrate in 25ml dH2O)












1ml solution B to 50 ml solution A
Folin Reagent




0.05% Tween 20 (0.5g)





Adjust to pH 7.0 and make up to 1L with distilled water
Working solution 4XSSC 
Dilute 20XSSC 1 in 5 with distilled water
1% Blocking Buffer
In 100ml
Fat free milk powder (1g)
1x TBST (100ml)
Non-Reducing Sample Application/Loading Buffer:
Glycerol (40-50%)
Bromophenol blue












Tris base (242 g)
Glacial acetic acid (57.1 ml)
0.5 M Na2 EDTA (100 ml)










2% SDS (20ml of 10% SDS)
0.5M NaCl (62.5g)
Make up to 100ml in 1M Tris-HCl pH 6.7
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